

FEB-16-07 FRI 05:48 PM

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:
GOLDENBERG
Serial No.: 09/965,796
Filed: October 1, 2001
Title: IMMUNOTHERAPY OF B-CELL
MALIGNANCIES USING ANTI-CD22
ANTIBODIES
Group Art Unit: 1643
Examiner: Alana M. Harris
Attorney Docket No.: IMMU:007US3

EFS-WEB**DECLARATION UNDER 37 CFR § 1.132**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. Box 1450
ALEXANDRIA, VA 22313-1450

Sir:

I, Kenneth Foon, being duly warned, declare as follows:

1. I am the Director of Clinical Investigation and Program Director for the Leukemia and Lymphoma Program at the University of Pittsburgh Cancer Institute. I have an extensive background in the field of immunotherapy for cancer treatment, as evidenced by my Curriculum Vitae, which is attached. In particular, I have been the principal investigator on clinical trials relating to immunotherapy of various B-cell malignancies. For example, I am currently the principal investigator for a Phase II clinical trial to study effects of a combination of rituximab, fludarabine and cyclophosphamide on patients with previously untreated chronic lymphocytic leukemia.

2. I am familiar with the article Maloney *et al.*, *Blood*, 84(8): 2457-2466 (1994). This article relates to results from a Phase I clinical trial to evaluate the safety of anti-CD20 antibody as a single agent therapeutic.

FEB-16-07 FRI 05:48 PM

FAX NO.

P. 06

SN 09/965,796

IMMU:007US3

3. Maloney 1994 states, on page 2465, that "extension of these studies to patients with minimal disease, using antibody alone or in combination with conventional therapies, may provide the greatest benefit. The disclosure in Maloney that anti-CD20 may be combined with a "conventional therapy" would not have suggested to me therapy with a combination of an anti-CD20 antibody and another antibody, such as an anti-CD22 antibody. This is because "conventional therapies" at the time of the Maloney article, circa 1994, were chemotherapies, not antibody therapies. The current clinical trial which I referenced above in paragraph 1 is just such a combination of the anti-CD20 antibody rituximab with a conventional drug therapy (fludarabine and cyclophosphamide) that is envisioned by Maloney 1994.

4. "Conventional" means "conforming to established practice or accepted standards; traditional" (The American Heritage® Dictionary of the English Language: Fourth Edition - 2000). An investigational drug in Phase I clinical trials cannot be considered a conventional therapy, i.e., it does not conform to established practice or accepted standards." By definition, investigational drugs have not been "accepted." Companies can provide investigational drugs to doctors if they are part of a drug trial covered by an FDA-approved protocol, and such drugs are by definition not conventional, since they are not available for use by any doctor on any patient.

5. In 1994 (and later) antibody therapies were not "conventional," and therefore Maloney's comment regarding the addition of "conventional therapies" to his anti-CD20 antibody suggests to a skilled clinician a combination of the anti-CD20 single antibody therapy with a chemotherapy. It would not have suggested therapy with a combination of antibodies. "Conventional therapies," circa 1994 and later, were chemotherapies. The first approved antibody for therapy of any malignancy was the anti-CD20 antibody rituximab that is the subject of Maloney, but it was not approved until 1997, and therefore there was no cancer therapy with any antibody that was a conventional therapy in 1994.

6. Treatment with anti-CD22 antibody was not conventional circa 1994. For example, Goldenberg et al., *J. Clin. Oncol.*, 9: 548-564 (1991) relates to results from a pilot Phase I study involving a small number of patients to see the feasibility of giving this radiolabeled antibody, involving targeting tumor and organs, doses delivered to tumor and normal organs, and any evidence of efficacy in a small number of patients, and does not establish that treatment with anti-CD22 antibody was "conventional." Juweid et al. *Cancer Res.*, 55:5899s-5907s (1995) is a follow-on report of further treatment of patients with low doses and

SN 09/965,796

IMMU:Q07US3

initial results of high dose therapy in a Phase I trial. Here again, these were early investigational studies and do not represent conventional therapy.

7. Current reviews and texts support the fact that antibody therapy using a combination of antibodies to different targets is not conventional. No such combination therapy has been approved, and even combinations of rituximab with conventional chemotherapy for lymphoma have only been approved by the FDA within the past two years. Although some articles began to discuss the possibility of combination antibody therapies following publication by Immunomedics of their studies of epratuzumab and rituximab in about 2002/2003, none of these indicate that such therapy is "conventional." For example, "What is New in Lymphoma," published in 2004, cites rituximab as an advancement in the treatment of NHL. Efforts to improve the activity of rituximab are noted, and include increasing the number of weekly infusions, delivering higher doses and increasing dose density. Combinations with CHOP are also mentioned. The article references both a Phase II study of a combination of rituximab with epratuzumab and a phase I/II study of the combination of galiximab and rituximab, both of which were reported in 2003, demonstrating that combination antibody therapy was still very much investigational at this later date. Cheson, CA Cancer J Clin, Sep-Oct; 54(5):260-72 (2004).

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

2/16/07

Date

K. Foon

K. Foon, MD

CURRICULUM VITAE

BIOGRAPHICAL

Name: Kenneth A. Foon, MD **Birth Date:** 3/7/47
Home Address: 416 William Street **Birth Place:** Detroit, MI
Pittsburgh, PA 15211
Home Phone: (412) 481-2724 **Citizenship:** USA
E-Mail Address: foonka@upmc.edu
Business Address: University of Pittsburgh Cancer Institute
Division of Hematology-Oncology
UPMC Cancer Pavilion
5150 Centre Ave., Suite 571
Pittsburgh, PA 15232
Business Phone: (412) 623-5898 **Spouse:** Rebecca A. Garrett, MD
Business Fax: (412) 648-6579

EDUCATION AND TRAINING

UNDERGRADUATE:

| Dates Attended | Name & Location of Institution | Degree Received and Year | Major Subject |
|-----------------------|---|---------------------------------|----------------------|
| 1964-1966 | University of Michigan | | |
| 1966-1968 | Wayne State University | BS, 1968 | Biology |

GRADUATE:

| Dates Attended | Name & Location of Institution | Degree Received and Year | Major Subject |
|-----------------------|---|---------------------------------|----------------------|
| 1968-1972 | Wayne State University | M.D, 1972 | Medicine |

POSTGRADUATE:

| Dates Attended | Name & Location of Institution | Name of Program Director and Discipline |
|-----------------------|--|---|
| 1972-1973 | University of California, San Diego School of Medicine, San Diego, CA | Nathan Zvailler, MD Straight Internal Medicine Internship |
| 1976-1977 | Washington VA & Georgetown Hospitals, District of Columbia | Hyman Zimmerman, MD Straight Internal Medicine First Year Residency |
| 1977-1980 | University of California, Los Angeles Los Angeles, CA | Martin Cline, MD Fellow in Hematology and Oncology |

ACADEMIC:

| Years Inclusive | Name & Location of Institution | Rank/Title |
|------------------------|--|---|
| 1980-1981 | University of California Los Angeles School of Medicine Los Angeles, CA | Assistant Professor of Medicine (tenure track) |
| 1985-1987 | University of Michigan School of Medicine Ann Arbor, MI | Associate Professor of Medicine (with tenure) |
| 1985-1987 | University of Michigan School of Medicine Ann Arbor, MI | Associate Chief, Div. of Hematology- Oncology Director of Clinical Hematology |
| 1987-1991 | State University of New York at Buffalo Buffalo, NY | Professor, Dept. of Medicine (with tenure) |
| 1987-1991 | Roswell Park Cancer Institute Buffalo, NY | Chief, Division of Clinical Immunology |
| 1991-1992 | Department of Molecular and Experimental Medicine, The Scripps Research Institute San Diego, CA | Adjunct Member |

| | | |
|--------------|--|---|
| 1991-1992 | Ida M. and Cecil H. Green Cancer Center Scripps Clinic and Research Foundation San Diego, CA | Associate Director for Clinical Research |
| 1993-1999 | University of Kentucky School of Medicine Lexington, KY | Chief, Div. of Hematology-Oncology Professor of Medicine (with tenure) |
| 1993-1999 | Markey Cancer Center University of Kentucky School of Medicine Lexington, KY | Director |
| 1999-2001 | University of Cincinnati School of Medicine Cincinnati, OH | Associate Director Division of Hematology-Oncology Professor of Medicine (with tenure) |
| 1999-2001 | Barrett Cancer Center University of Cincinnati School of Medicine Cincinnati, OH | Director |
| 2001-2003 | Stanford University School of Medicine Stanford, CA | Clinical Professor of Medicine |
| 2003-2006 | University of Pittsburgh Cancer Institute | Co-Leader of the Biological Therapeutics Program |
| 2005-Present | University of Pittsburgh Cancer Institute | Interim Director of Minority Outreach |
| 2003-Present | University of Pittsburgh Cancer Institute | Director of Clinical Investigations Co-Leader of the Hematologic Malignancies Program |
| 2003-Present | University of Pittsburgh School of Medicine | Professor of Medicine |

NON-ACADEMIC

| Years Inclusive | Name & Location of Institution | Rank/Title |
|------------------------|---|--|
| 1973-1975 | National Eye Institute, National Institutes of Health Bethesda, MD and guest worker National Institute of Dental Research, Laboratory of Microbiology and Immunology Bethesda, MD | Research Associate and Lieutenant, U.S. Public Health Service |
| 1975-1976 | National Institute of Dental Research, Laboratory of Microbiology and Immunology, National Institute of Health, Bethesda, MD | Clinical Associate and Lieutenant Commander, U.S. Public Health Service |
| 1981-1982 | Head, Monoclonal Antibody- Hybridoma Section, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute Frederick, MD | Senior Investigator and Lieutenant Commander, U.S. Public Health Service |
| 1982-1985 | Head, Clinical Investigations Section, Biologic Response Modifiers Program, Division of Cancer Treatment National Cancer Institute Frederick, MD | Senior Investigator and Lieutenant Commander, U.S. Public Health Service (tenured in 1984) |
| 2001-2003 | Abgenix Inc. Fremont, CA | Director, Clinical Development for Oncology |

CERTIFICATION AND LICENSURE

Specialty Certification:

| Certifying Board | Year |
|-------------------------|-------------|
|-------------------------|-------------|

| | |
|---|------|
| National Board of Medical Examiners | 1973 |
| American Board of Internal Medicine | 1978 |
| American Board of Internal Medicine Subspecialty of Hematology | 1980 |
| American Board of Internal Medicine Subspecialty of Medical Oncology | 1981 |

Medical Licensure:

| Licensing Board/State | Year |
|-----------------------|------|
| California (active) | 1973 |
| Maryland (inactive) | 1973 |
| Michigan (inactive) | 1982 |
| New York (inactive) | 1987 |
| Kentucky (inactive) | 1993 |
| Ohio (inactive) | 1999 |
| Pennsylvania (Active) | 2003 |

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

| Organization | Year |
|---|--------------|
| American College of Physicians (Fellow) | 1978-present |
| American Society of Hematology | 1980-present |
| American Association for the Advancement of Sciences | 1980-present |
| American Society of Clinical Oncology | 1981-present |
| American Association for Cancer Research | 1982-present |
| The Society of Biological Therapy | 1982-present |

| | |
|---|--------------|
| Clinical Immunology Society | 1987-present |
| Member, Leukemia Committee, Southwest Oncology Group | 1987-2001 |
| International Society for Experimental Hematology | 1991 |
| Member, Colorectal Disease Committee, National Surgical Adjuvant Breast and Bowel Project | 1997-2001 |
| Member, Melanoma Committee, Southwest Oncology Group | 1997-2000 |
| Member, Colorectal Committee, American College of Surgeons | 1999-2001 |
| Member, Lymphoma, Committee, Eastern Cooperative Oncology Group | 2003-Present |
| Member, Leukemia Committee, ECOG | 2003-Present |

HONORS

| Title of Award | Year |
|--|-------------|
| Alpha Omega Alpha | 1971 |
| Dr. A. Ashley Rousuck Award in Internal Medicine (Wayne State University School of Medicine) | 1971 |
| Gordon B. Myers Award in Internal Medicine (Wayne State University School of Medicine) | 1972 |
| Medical Degree Awarded with High Distinction, Wayne State University | 1972 |
| Fellow of the American College of Physicians | 1982 |
| Distinguished Alumni Award, Wayne State University School of Medicine | 1987 |

| | |
|---|------|
| Michigan Science Trailblazer | 1988 |
| Faculty Research Award for Excellence in Research, University of Kentucky | 1998 |
| Chairman's Award for Excellence in Research, University of Kentucky, Dept. of Internal Medicine | 1998 |

PUBLICATIONS

1. Refereed Articles

1. **Foon KA**, Wahl SM, Oppenheim JJ and Rosenstreich DL: Serotonin-induced production of a monocyte chemotactic factor by human peripheral blood leukocytes. *J Immunol* 117:154-1552, 1976.
2. Sher NA, **Foon KA**, Fishman ML and Brown T: Demonstration of monocyte chemotactic factors in the aqueous humor during experimental immunogenic uveitis in the rabbit. *Infect Immun* 13:1110-1116, 1976.
3. Sher ND, Douglas DJ, Mindrup E, Minaii LA and **Foon KA**: Macrophage migration inhibition factor activity in the aqueous humor during experimental corneal xenograft and allograft rejection. *Am J Ophthalmol* 82:858-865, 1976.
4. **Foon KA**, Yuen K, Ballantine E and Rosenstreich D: Analysis of the systemic corticosteroid sensitivity of patients with primary open angle glaucoma. *Am J Ophthalmol* 83:167-173, 1977.
5. **Foon KA**, Naiem F, Yale C and Gale RP: Acute myelogenous leukemia: Morphologic subclass and response to therapy. *Leuk Res* 3:171-173, 1979.
6. **Foon KA**, Billing RJ and Terasaki PI: Dual B and T markers in acute and chronic lymphocytic leukemia. *Blood* 55:16-20, 1980.
7. Billing RJ, Clark BM, Koeffler P, **Foon KA** and Terasaki PI: Acute myelocytic leukemia heteroantisera. *Clin Immunol Immunopathol* 16:202-210, 1980.

8. **Foon KA**, Yale C, Clodfelter K and Gale RP: Effect of posttreatment hepatitis on survival of patients with acute myelogenous leukemia. *JAMA*, 244:1806-1807, 1980.
9. **Foon KA**, Fitchen JH, Billing RJ, Belzer MB, Terasaki PI and Cline MJ: An antithymocyte serum non-cytotoxic to myeloid progenitor cells: Candidate serum for prevention of graft-versus-host disease in bone marrow transplantation. *Clin Immunol Immunopathol* 16:416-422, 1980.
10. **Foon KA**, Billing RJ, Terasaki PI and Cline MJ: Immunologic classification of acute lymphocytic leukemia: Implications for normal lymphoid differentiation. *Blood* 56:1120-1126, 1980.
11. **Foon KA**, Herzog P, Billing R, Terasaki PI and Feig S: Immunologic classification of childhood acute lymphocytic leukemia. *Cancer* 47:280-284, 1981.
12. **Foon KA**, Naeim F, Saxon A, Stevens R and Gale RP: Leukemia of T-helper lymphocytes: Clinical and functional characterization. *Leuk Res* 5:1-10, 1981.
13. **Foon KA**, Billing RJ, Fitchen JH, Belzer MB, Drew SI and Terasaki PI: An antigen expressed by cells of the myelo-monocytic lineage. *Am J Hematol* 10:259-267, 1981.
14. Belzer M, Fitchen JH, Ferrone S, **Foon KA**, Billing RJ and Golde DW: Expression of HLA-DR antigen on human erythroid progenitor cells as determined by monoclonal anti-DR antibodies and heteroantisera. *Clin Immunol Immunopathol* 20:111-115, 1981.
15. Gale RP, **Foon KA**, Cline MJ and Zighelboim J: Intensive chemotherapy for acute myelogenous leukemia. *Ann Intern Med* 94:753-757, 1981.
16. Fitchen JH, **Foon KA** and Cline MJ: The antigenic characteristics of hematopoietic stem cells. *N Engl J Med* 305:17-25, 1981.
17. **Foon KA**, Zighelboim J, Yale C and Gale RP: Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. *Blood* 58:467-470, 1981.
18. **Foon KA**, Filderman A and Gale RP: Histiocytic lymphoma following resolution of sarcoidosis. *Med Pediatr Oncol* 9:325-331, 1981.
19. Hoffman F, **Foon KA**, Smith D, Kransler J, Caciarelli J and Billing R: Functional properties of subsets of T lymphocytes defined by special antigens. *Clin Exp Immunol* 44:476-484, 1981.
20. Hocking WG, Billing R.J, **Foon KA** and Golde DW: Human alveolar macrophages express DR antigens. *Blood* 58:1040-1042, 1981.
21. Linker-Israeli M, Billing RJ, **Foon KA** and Terasaki PI: Monoclonal antibodies reactive with acute myelogenous leukemia cells. *J Immunol* 127:2473-2477, 1981.

22. Billing R, Terasaki PI, Sugich L and **Foon KA**: Detection of differentiation antigens by use of monoclonal antibodies. *J Immunol Methods* 47:289-294, 1981.
23. Schroff RW, **Foon KA**, Billing RJ and Fahey JL: Immunologic classification of lymphocytic leukemias based on monoclonal antibody-defined cell surface antigens. *Blood* 59:207-215, 1982.
24. **Foon KA** and Haskell CM: Inadvertent overdose with lomustine (CCNU) followed by hematologic recovery. *Cancer Treat Reports* 66:1241-1241, 1982.
25. **Foon KA** and Gale RP: Controversies in the therapy of acute myelogenous leukemia. *Am J Med* 72:963-979, 1982.
26. **Foon KA**, Schroff RW and Gale RP: Cell surface markers on leukemia and lymphoma cells: Recent advances. *Blood* 60:1-19, 1982.
27. Billing RJ, **Foon KA** and Linker-Israeli M: The immunological classification of leukemia based on a rapid microcytotoxicity test. *Clin Exp Immunol* 49:142-148, 1982.
28. Schroff RW and **Foon KA**: Heterogeneity in a lymphoid tumor: Co-expression of T and B surface markers. *Blood* 60:373-380, 1982.
29. **Foon KA**, Schroff RW and Fliegel S: Monoclonal antibody characterization of plasmacytoma cells associated with T lymphocytes with a suppressor phenotype. *Clin Immunol Immunopathol* 25:59-66, 1982.
30. **Foon KA**, Bernhard MI and Oldham RK: Monoclonal antibody therapy: Assessment by animal tumor models. *J Biol Response Mod* 1:277-304, 1982.
31. Sherwin SA, Knost JA, Fein S, Abrams PG, **Foon KA**, Ochs JJ, Schoenberger C, Maluish AE and Oldham RK: A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients. *JAMA* 248:2461-2466, 1982.
32. Key ME, Bernhard MI, Hoyer LC, **Foon KA**, Oldham RK and Hanna MG: Guinea pig line 10 hepatocarcinoma model for monoclonal antibody serotherapy: *In vivo* localization of a monoclonal antibody in normal and malignant tissues. *J Immunol* 120:1451-1457, 1983.
33. Sherwin SA, Mayer D, Ochs JJ, Abrams PG, Knost JA, **Foon KA**, Fein S and Oldham RK: Recombinant leukocyte A interferon in advanced breast cancer: Results of a Phase II efficacy trial. *Ann Intern Med* 98:598-602 1983.
34. Bernhard MI, **Foon KA**, Oeltmann TN, Key ME, Hwang KM, Clarke CG, Christensen WL, Hoyer LC, Hanna MG and Oldham RK: Guinea pig line 10 hepatocarcinoma model:

Characterization of monoclonal antibody and *in vivo* effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res 43:4420-4428, 1983.

35. Bernhard MI, Hwang KM, **Foon KA**, Keenan A, Kessler R, Frincke, Tallum DJ, Hanna MG, Peters L and Oldham RK: Localization of ¹¹¹In- and ¹²⁵I-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors. Cancer Res 43:4429-4433, 1983.
36. **Foon KA**, Smalley RV, Riggs CW and Gale RP: The role of immunotherapy in acute myelogenous leukemia. Arch Intern Med 143:1726-1734, 1983.
37. Knost JA, Sherwin SA, Abrams PG, Ochs JJ, **Foon KA**, Williams R, Tuttle R and Oldham RK: The treatment of cancer patients with human lymphoblastoid interferon: A comparison of two routes of administration. Cancer Immunol Immunother 15:148-155, 1983.
38. Abrams PG, Knost JA, Clarke G, Wilburn S, Oldham RK and **Foon KA**: Determination of the optimal human cell lines for development of human hybridomas. J Immunol 131:1201-1204, 1983.
39. **Foon KA**, Buescher S, Kimball ES, Huang LC, Stevenson HC, Clarke G, Gregoria T and Harley JB: Monoclonal antibody to human eosinophils recognizing 95 kD surface membrane antigen. Hybridoma 2:393-402, 1983.
40. Stevenson HC, **Foon KA**, Kanapa DJ, Favilla T, Beman J and Oldham RK: The potential value of cytapheresis for adoptive immunotherapy of cancer patients. Plasma Ther Transfus Technol 5:237-250, 1984.
41. Hwang JM, **Foon KA**, Cheung PH, Pearson JW and Oldham RK: Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res 44:4578-4586, 1984.
42. **Foon KA**, Mutsuyasu RT, Schroff RW, McIntyre RE, Champlin R and Gale RP: Immune deficiency in young males with hepatitis-associated severe aplastic anemia. Ann Intern Med 100:657-662, 1984.
43. Oldham RK, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG and **Foon KA**: Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospects. Med Oncol Tumor Pharmacother 1:51-62, 1984.
44. Abrams PG, Ochs JJ, Giardina SL, Morgan AC, Wilburn SB, Wilt AR, Oldham RK and **Foon KA**: Production of large quantities of human immunoglobulin in the ascites of athymic mice: Implication for the development of anti-human idiotype monoclonal antibodies. J Immunol 132:1611-1613, 1984.

45. Stevenson HC, Ochs JJ, Halverson L, Oldham RK, Sherwin SA and **Foon KA**: Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications. Am J Med 77:355-358, 1984.
46. Fer MF, Beman J, Stevenson HC, Maluish A, Moratz C, **Foon KA**, Herberman RB, Oldham RK, Terman DS, Young JB and Daskal Y: A trial of autologous plasma perfusion over protein A in patients with breast cancer. J Biol Response Mod 3:352-358, 1984.
47. Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, **Foon KA** and Zighelboim J: Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. Lancet 1:894-896, 1984.
48. Schroff RW, Farrell MM, Klein RA, Oldham RK and **Foon KA**: T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol 133:1641-1648, 1984.
49. **Foon KA**, Neubauer RH, Wikstrand CJ, Schroff RW, Rabin H and Seeger RC: Human Thy-1 antigen: Distribution on human and non-human primate hematopoietic cells. J Immunogenet 11:233-244, 1984.
50. **Foon KA**, Schroff RW, Bunn RA, Mayer D, Abrams PG, Fer MF, Ochs JJ, Bottino GC, Sherwin SA, Herberman RB and Oldham RK: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085-1094, 1984.
51. Oldham RK, **Foon KA**, Morgan AC, Woodhouse C, Schroff RW, Abrams PG, Fer MF, Schoenberger C, Farrell M, Kimball E and Sherwin SA: Monoclonal antibody therapy of malignant melanoma: *In vivo* localization in cutaneous metastasis after intravenous administration. J Clin Oncol 2:1235-1244, 1984.
52. Reynolds CW and **Foon KA**: T-lymphoproliferative disease and related disorders in man and experimental animals. A review of the clinical, cellular and functional characteristics. Blood 64:1146-1158, 1984.
53. Fer MF, Bottino GC, Sherwin SA, Hainesworth JD, Abrams PG, **Foon KA** and Oldham, RK: Atypical tumor lysis syndrome in a patient with T-cell lymphoma following recombinant interferon therapy. Am J Med 77:953-956, 1984.
54. Bunn PA, **Foon KA**, Idhe DC, Winkler CF, Zeffren J, Sherwin SA and Oldham RK: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphoma. Ann Intern Med 101:484-487, 1984.
55. Stevenson HC, Kimball ES, Buescher S, Clarke G and **Foon KA**: Monoclonal antibody to human monocytes and granulocytes: Isolation of membrane antigens and lack of effect on leukocyte functions *in vitro*. Hybridoma 3:247-261, 1984.

56. **Foon KA**, Sherwin SA, Abrams PG, Longo DL, Fer MF, Stevenson HC, Ochs JJ, Bottino GC, Schoenberger CS, Zeffren J, Jaffe ES and Oldham RK: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. *N Engl J Med* 311:1148-1152, 1984.
57. Morgan AC, Woodhouse CS, Knost JA, Abrams PG, Clarke GC, Arthur LO, McIntrye R, Ochs JJ, **Foon KA**, Hanna MG and Oldham RK: Monoclonal antibodies to human colorectal tumor-associated antigens: Improved elicitation and subclass restriction. *Hybridoma* 3:233-245, 1984.
58. Sherwin SA, **Foon KA**, Oldham RK, Abrams PG, Heyman MR, Ochs JJ, Watson R and Maluish A: A preliminary phase I trial of partially purified interferon-gamma (IFN-gamma) in patients with disseminated cancer. *Biol Response Mod* 3:599-607, 1984.
59. Bunn PA, Carrasquillo JA, Keenan AM, Schroff RW, **Foon KA**, Hsu SM, Gazdar AF, Reynolds JJ, Perentesis P and Larson SM: Imaging of T-cell lymphoma by radiolabeled monoclonal antibody. *Lancet* 1219-1221, 1984.
60. Wei N and **Foon KA**: Sclerodactyly in a patient with mycosis fungoides. *Arch Intern Med* 145:139-140 1985.
61. Schroff RW, **Foon KA**, Wilburn SB, Oldham RK and Morgan AC: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. *Cancer Res* 45:879-885, 1985.
62. Schroff RW, Woodhouse CS, **Foon KA**, Farrell MM, Klein RA, Oldham RK and Morgan AC: Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. *J Natl Cancer Inst* 74:299-306, 1985.
63. **Foon KA**, Bottino GC, Abrams PG, Fer MF, Longo DL, Schoenberger CS and Oldham RK: A phase II trial of recombinant leukocyte A interferon for patients with advanced chronic lymphocytic leukemia. *Am J Med* 78:216-220, 1985.
64. Gale RP and **Foon KA**: Chronic lymphocytic leukemia: Recent advances in biology and treatment. *Ann Intern Med* 103:101-120, 1985.
65. Giardina SL, Schroff RW, Woodhouse CS, Golde DW, Oldham RK, Cleary ML, Sklar J, Pritikin N and **Foon KA**: Detection of two malignant B-cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin gene rearrangement. *Blood* 66:1017-1021, 1985.
66. Giardina SL, Schroff RW, Kipps TJ, Woodhouse CS, Abrams PG, Rager HC, Morgan AC and **Foon KA**: The generation of monoclonal anti-idiotype antibodies to human B-cell derived leukemias and lymphomas. *J Immunol* 135:653-658, 1985.

67. **Foon KA**, Rossio JL, Schroff RW, Wahl SM, Abrams PG, Rager HC, Pickeral SF and Fidler IJ: The generation of stable human T-cell hybridomas which constitutively produce interleukin-2 and chemotactic factor. *Hybridoma* 4:211-222, 1985.
68. Stevenson HC, Abrams PG, Schoenberger CS, Smalley RV, Herberman RB and **Foon KA**: A phase I evaluation of poly ICLC in cancer patients. *J Biol Response Mod* 4:650-655, 1985.
69. **Foon KA**, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK and Herberman RB: A phase I trial of recombinant gamma interferon in patients with cancer. *Cancer Immunol Immunother* 20:193-197, 1985.
70. Maluish AE, Reid JW, Crisp EA, Overton WR, Levy H, **Foon KA** and Herberman RB: Immunomodulatory effects of Poly (I,C)-LC in cancer patients. *J Biol Response Mod* 4:656-663, 1985.
71. **Foon KA**, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Poole M, Schnipper EF, Jaffe ES and Herberman RB: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: Therapeutic and immunologic results. *Am J Med* 80:351-356, 1986.
72. Bunn PA Jr, Ihde DC and **Foon KA**: The role of recombinant leukocyte A interferon in the therapy of cutaneous T-cell lymphomas. *Cancer* 57:1315-1321, 1986.
73. **Foon KA** and Todd RF III: Immunologic classification of leukemia and lymphoma. *Blood* 68:1-31, 1986.
74. Giardina SL, **Foon KA**, Beatty SM and Morgan AC Jr: Evaluation of alternative methodologies for the generation of monoclonal anti-idiotypic antibodies to human B-cell derived leukemias and lymphomas. *J Immunol Methods* 89:1-7, 1986.
75. Faltynek CR, Princler GL, Ruscetti FW, Maluish AE, Abrams PG and **Foon KA**: Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. *Blood* 68:297-300, 1986.
76. **Foon KA**, Nakano GM, Koller CA, Longo DL and Steis RG: Response to 2'-deoxycoformycin after failure of interferon alpha in non-splenectomized patients with hairy cell leukemia. *Blood* 68:297-300, 1986.
77. MS and **Foon KA**: Alpha interferon in the treatment of hematologic malignancies. *Am J Med* 81:871-882, 1986.
78. Carrasquillo JA, Bunn PA Jr, Keenan AM, Reynolds JC, Schroff RW, **Foon KA**, Ming-Hsu S, Gazdar AR, Mulshine JL, Oldham RK, Perentesis P, Horowitz M, Eddy J, James P and Larson SM: Radio-immunodetection of cutaneous T-cell lymphoma with ^{111}In -T101 monoclonal antibody. *N Engl J Med* 315:673-680, 1986.

79. Crasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, **Foon KA**, Schroff RW, Perentesis P, Steiss RG, Keenan AM, Horowitz M and Larson SM: Tumor imaging of ^{111}In T-101 monoclonal antibody is superior to ^{131}I T-101 in cutaneous T-cell lymphoma. *J Nucl Med* 28:281-287, 1987.
80. Schroff RW, Morgan AC, Woodhouse CS, Abrams PG, Farrell MM, Carpenter BE, Oldham RK and **Foon KA**: Monoclonal antibody therapy in malignant melanoma: Factors effecting *in vivo* localization. *J Biol Response Mod* 6:457-472, 1987.
81. Kahn P, Roth MS, Keren DF and **Foon KA**: Light chain disease associated with the hyperviscosity syndrome. *Cancer* 60:2267-2268, 1987.
82. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, **Foon KA**, Reynolds JC, Schroff RW, Morgan AC, Larson SM and Weinstein JN: Kinetic model for the biodistribution of an ^{111}In -labeled monoclonal antibody in humans. *Cancer Res* 47:1-9 1987.
83. Stevenson HC, Keenan AM, Woodhouse C, Ottow RT, Miller P, Stellar EP, **Foon KA**, Abrams PG, Beman J, Larsen SM and Sugarbaker PH: Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. *Cancer Res* 47:6100-6103, 1987.
84. Keenan AM, Weinstein JN, Carrasquillo JA, Bunn PA Jr, Reynolds JC, **Foon KA**, et al: Immunolymphoscintigraphy and the dose-dependence of Indium 111 labeled T-101 monoclonal antibody in patients with cutaneous T-cell lymphoma. *Cancer Res* 47:6093-6097, 1987.
85. Carrasquillo JA, Abrams P, Schroff R, Reynolds J, Morgan C, Keenan A, **Foon KA**, Perentesis P, Marshall S, Horowitz M, Szimendera J, Oldham R and Larson SM: Effect of ^{111}In -9.2.27 monoclonal antibody dose on the imaging of metastatic melanoma. *J Nucl Med* 29:39-47 1988.
86. Second MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukemias. *Cancer Genet Cytogenet* 30:1-15, 1988.
87. Buchsbaum DJ, Sinkule JA, Stites MS, Fodor PA, Hanna DE, Ford SM, Warber-Matich SL, June JE and **Foon KA**: Localization and imaging with radioiodine-labeled monoclonal antibodies in xenogeneic tumor model for human B-cell lymphomas. *Cancer Res* 48:2475-2482, 1988.
88. Gale RP and **Foon KA**: Daunorubicin or doxorubicin in acute myelogenous leukemia? *Leukemia* 2:209-210, 1988.

89. Third MIC Cooperative Study Group: Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. *Cancer Genet Cytogenet* 32:1-10, 1988.
90. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized controlled clinical trial. *N Engl J Med* 319:902-907, 1988.
91. Cheson BD, Bennett JM, Rai KR, Greaves MR, Kay NE, Schiffer CA, Keating MJ, Kempin SJ, Boldt DH and **Foon KA**: Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL): Recommendations of the NCI-sponsored working group. *Am J Hematol* 29:152-163, 1988.
92. **Foon KA**, Doroshow J, Bonnem E, Fefer A, Graham S, Grosh B, Narayan P, Elias L, Harvey H, Schulof R, Williams R, Rinehart J, Zekan P, Catalona W, Dillman R, Salmon S and Galasso F: A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. *J Biol Response Mod* 7:540-545, 1988.
93. **Foon KA**: Biological response modifiers: The new immunotherapy. *Cancer Res* 49:1621-1639 1989.
94. Biddle W, Pancook J, **Foon KA**, Goldrosen M and Vaickus L: Lym-1 antibody-dependent cell-mediated cytotoxicity by an anti-Class II murine monoclonal antibody: Effects of recombinant IL-2 on human effector cell lysis of human B-cell tumors. *Cancer Res* 50:2991-2996, 1990.
95. **Foon KA**, Rai KR and Gale RP: Chronic lymphocytic leukemia: New insights into biology and therapy. *Ann Intern Med* 113:525-539, 1990.
96. Fanning J, Biddle WC, Goldrosen M, Crickard K, Crickard U, Piver S and **Foon KA**: Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. *Gynecol Oncol* 39:119-122, 1990.
97. Vaickus L, Biddle W, Cemerlic D and **Foon KA**: Gamma interferon augments Lym-1-dependent, granulocyte and mononuclear cell-mediated tumor lysis. *Blood* 75:2408-2416, 1990.
98. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, **Foon KA** and Köhler H: Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. *J Immunol* 145:2758-2765, 1990.
99. Chatterjee M, Barcos M, Han T, Liu X, Bernstein Z and **Foon KA**: Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. *Blood* 76:1825-1829, 1990.

100. Goldrosen MH, Biddle WC, Pancook J, Bakshi S, Vanderheyden JL, Morgan AC, **Foon KA**: Biodistribution, pharmacokinetic and imaging studies with ^{186}Re -labeled NR-LU-10 in LS174T colonic tumor-bearing mice. *Cancer Res* 50:7973-7978, 1990.
101. VanderMolen LA, Steis RG, Duffey PL, Urba WJ, **Foon KA**, Smith SW II, Clark JW, Conlon K, Stevenson HC, Hartmann LC, Watson T, Jaffe ES and Longo DL: Low- vs high-dose interferon alfa-2a in relapsed low-grade non-Hodgkin's lymphoma. *J Natl Cancer Inst* 82:235-238, 1990.
102. **Foon KA** and Fanning J. Immunotherapy of gynecologic malignancies. *Semin Surg Oncol*. 6:364-368, 1990.
103. Bernstein ZP, Vaickus L, Friedman N, Goldrosen MH, Watanabe H, Rahman R, Arbuck SG, Sweeney J, Vesper D, Henderson ED, Zeffren J, Dennin RA, Levitt D and **Foon KA**: IL-2 LAK therapy of non-Hodgkin's lymphoma and Hodgkin's disease. *J Immunother* 10:141-146, 1991.
104. Rahman R, Bernstein Z, Vaickus L, Penetrante R, Arbuck S, Kopec I, Vesper D and **Foon KA**: Unusual gastrointestinal complications of interleukin-2 and lymphokine-activated killer cell therapy. *J Immunother* 10:221-225 1991.
105. Bernstein ZP, Goldrosen MH, Vaickus L, Friedman N, Watanabe H, Rahman R, Park J, Arbuck SG, Sweeney J, Vesper D, Takita H, Zeffren J, Dennin RA and **Foon KA**: Interleukin-2 with *ex vivo*-activated killer cells: Therapy of advanced non-small-cell lung cancer. *J Immunother* 10:383-387, 1991.
106. Vaickus L, Ball ED and **Foon KA**: Immune markers in hematologic malignancies. *Crit Rev Oncol/Hematol* 11:267-297, 1991.
107. **Foon KA**, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell DF, Walker RA, Darrow TL, Linna TJ, Farmer DL, Lynch WJ Jr, Huben R and Goldrosen MH: Renal cell carcinoma treated with continuous infusion interleukin-2 with *ex vivo*-activated killer cells. *J Immunother* 11:184-190, 1992.
108. Baer MR, Ozer H and **Foon KA**: Interferon-alpha therapy during pregnancy in chronic myelogenous leukemia and hairy cell leukemia. *Br J Haematol* 81:167-169, 1992.
109. **Foon KA** and Gale RP: Is there a T-cell form of chronic lymphocytic leukemia: Fact or fiction? *Leukemia* 6:867-868, 1992.
110. **Foon KA** and Piro LD. Lymphocytic leukemias: New insights into biology and therapy. *Leukemia* 6:26-32, 1992.
111. Watanabe H, Narumi K, Stewart CC, Arbuck SG, **Foon KA** and Goldrosen MH: The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. *Anticancer Res* 12:1925-33, 1992.

112. Bernstein ZP, Fitzpatrick JE, O'Donnell A, Han T, **Foon KA** and Bhargava A: Clinical significance of monoclonal proteins in chronic lymphocytic leukemia. Leukemia 6:1243-45, 1992.
113. **Foon KA**, Thiruvengadam R, Saven A, Bernstein ZP, Gale RP: Genetic relatedness of lymphoid malignancies: Transformation of chronic lymphocytic leukemia as a model. Ann Int Med 119:63-73, 1993.
114. Chatterjee M, **Foon KA**, Mukerjee S, Petrelli N and Köhler H. Idiotype matching: a network antigen idiotype is expressed in colon cancer patients' sera. Vaccine Res. 2:283-290, 1993.
115. Saven A, **Foon KA**, Piro LD: 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans'-cell histiocytosis. Ann Int Med 15;121:430-432, 1994.
116. Bhattacharya-Chatterjee M, **Foon KA** and Köhler H. Anti-idiotypic antibodies: Novel therapeutic approaches to the acquired immune deficiency syndrome and cancer. Clin Immunol. Immunother 38:75-82, 1994.
117. **Foon KA**, Chakraborty M, John WJ, Sherratt A, Köhler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine. J Clin Invest 96:334-342, 1995.
118. Chakraborty M, Mukerjee S, **Foon KA**, Köhler H, Ceriani RL, Bhattacharya-Chatterjee M. Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotypic antibody: Anti-idiotypic mimicking a breast cancer antigen in monkeys. Cancer Res 55:1525-1530, 1995.
119. **Foon KA**, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, Pincus S, Köhler H, Seon B, Tahaoglu E, Beers T, Chakraborty M, Bhattacharya-Chatterjee M. Immune responses in patients with cutaneous T-cell lymphoma treated with an anti-idiotypic antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1:1285-1294, 1995.
120. Chakraborty, M, **Foon KA**, Köhler H and Bhattacharya-Chatterjee M. Preclinical evaluation in non-human primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. J Immunotherapy 18:95-103, 1995.
121. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Marciniak E, Munn RK, Messino MJ, Macdonald JS, Bishop MR, Rayens MK, Thompson JS, **Foon KA**. Allogeneic bone marrow transplantation with partially matched related donors for advanced acute lymphoblastic leukemia in children and adults. Bone Marrow Transplant; 17:917-22, 1996.

122. Sen G, Chakraborty M, **Foon KA**, Reisfeld RA, Bhattacharya-Chatterjee M. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. *J Immunother* 21:75-83, 1997.
123. Jennings CD and **Foon KA**. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. *Blood* 90:2863-92, 1997.
124. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, **Foon KA**, Chatterjee SK. Induction of anti-tumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. *Cancer Res* 57:728-734, 1997.
125. **Foon KA**, John WJ, Chakraborty M, Sherratt A, Garrison J, Flett M, Bhattacharya-Chatterjee M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. *Clin Cancer Res* 3:1267-1276, 1997.
126. Sen G, Chakraborty M, **Foon KA**, Reisfeld RA, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of an anti-idiotype antibody that mimicks the disialoganglioside GD2. *Clin Cancer Res* 3:1969-1976, 1997.
127. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, **Foon KA**, Liles T-M, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* 90:2188-2195, 1997.
128. Davis BH, Foucar K, Szczarkowski, Ball E, Witzig T, **Foon KA**, Wells D, Dotyo P, Johnson R, Hanson C, Bessman D. U.S.-Canadian Consensus Recommendations on the Immunophenotypic Analysis of Hematologic Neoplasm by Flow Cytometry: Medical Indications. *Cytometry (Communications in Clinical Cytometry)* 30:249-263, 1997.
129. Jennings CD and **Foon KA**. Flow cytometry: recent advances in diagnosis and monitoring of leukemia. *Cancer Invest.* 15:384-99, 1997.
130. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, **Foon KA**, Markesberry WR, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. *JAMA* 280:1485-9, 1998.
131. Chatterjee SK, Tripathi PK, Chakraborty M, Yannelli J, Wang H, **Foon KA**, Maier CC, Blalock EJ and Bhattacharya-Chatterjee M. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. *Cancer Res.* 58:1217-1224, 1998.
132. **Foon KA**, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, Chakraborty M, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M. Antibody response in melanoma patients

- immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res. 4:1117-1124, 1998.
133. Tripathi PK, Qin H, Deng S, Xu C, Bhattacharya-Chatterjee M, **Foon, KA** and Chatterjee S. Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Mol Immunol. 35:853-63, 1998.
134. Sen G, Chakraborty M, **Foon KA**, Reisfeld RA and Bhattacharya-Chatterjee MB. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J Immunother. 21:75-83, 1998.
135. **Foon KA**, Yannelli J, Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res. 5:225-236, 1999.
136. Tripathi, PK, Quin H-X, Bhattacharya-Chatterjee M, Ceriani RL, **Foon KA**, and Chatterjee SK. Construction and characterization of a chimeric fusion protein consisting of an anti- idiotypic antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma18:193-202, 1999.
137. **Foon KA**, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, and Chatterjee M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 17:2889-2895, 1999.
138. **Foon KA**, Lutzky J, Rathindra BN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, and Chatterjee M. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 18:376-384, 2000.
139. Reece D, **Foon KA**, Bhattacharya-Chatterjee M, Hale GA, Howard DS, Munn RK, Nath R, Plummer BA, Teitelbaum A and Phillips GL. Use of the anti-idiotype antibody vaccine Tri-Ab after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant. 26:729-35, 2000.
140. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, **Foon KA** and Chatterjee SK. Construction and characterization of DNA vaccines encoding the single chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Therapy 7:1426-1436, 2000.
141. Baral R, Sherrat A, Das R, **Foon KA** and Bhattacharya-Chatterjee M. Murine monoclonal anti-idiotype antibody as a surrogate antigen for human HER2/Neu. Int J Cancer 92:88-95, 2001
142. **Foon KA** and Bhattacharya-Chatterjee M. Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 7:1154-1162, 2001

143. Qin H-X, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, **Foon KA**, O'Malley BW and Chatterjee, SK. Therapy of head and neck cancer by recombinant vaccinia virus expressing IL-2 in a murine model with evidence of immune suppression Mol Ther 4:551-558, 2001.
144. Reece DE, **Foon KA**, Bhattacharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, DiPersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL. Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin Breast Cancer 2:52-58, 2001.
145. Reece DE, **Foon KA**, Battarchaya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL. Use of the Anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin Breast Cancer. 2003 Feb; 3 Suppl 4:S152-7.
146. Saha A, Chatterjee SK, **Foon KA**, Primus FJ, Bhattacharya-Chatterjee M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res. 2003 Jun 1;63 (11):2844-54.
147. **Foon KA**, Yang XD, Weiner, LM, Belldegrun AS, Figlin RA, Crawford, J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz, G, Bukowski RM, Roskos, LK, Schwab GM. Preclinical and Clinical Evaluations of ABX-EGF, A Fully Human Anti-epidermal Growth Factor Receptor Antibody. Int J Rad Onc Biol Phys 58:3, 2004.
148. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, **Foon KA**, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004 Aug 1; 22 (15):3003-15. Epub 2004 Jun 21.
149. Saha A., Chatterjee SK, **Foon KA**, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res. 2004 Jul 15;64(14):4995-5003.
150. Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, **Foon KA**, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother. 2006 May;55(5):515-27. Epub 2005 Jul 26:1-13.
151. Palena C, **Foon KA**, Panicali D, Gomez Yafal A, Chinsangaram J, Hodge JW, Schlom J, Tsang KY. A potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for

- multiple costimulatory molecules. *Blood*. 2005 Nov 15; 106(10): 3515-23. Epub 2005 Aug 4.
152. Saha A, Chatterjee SK, **Foon KA**, Bhattacharya-Chatterjee M. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. *Immunology*, 2006 Aug; 118(4):483-96.
 153. Jacobs SA, **Foon KA**. Monoclonal antibody therapy of leukemias and lymphomas. *Expert Opin Biol Ther*. 2005 Sep; 5(9):1225-43.
 154. Hussein MA, Gundacker H, Head DR, Elias L, **Foon KA**, Boldt DH, Dobin SM, Dakhil SR, Budd GT, Appelbaum FR. Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706. *Leukemia*. 2005 Nov; 19(11):1880-6.
 155. Brickner AG, Evans AM, Mito JK, Xuereb SM, Feng X, Nishida T, Fairfull L, Ferrell RA, **Foon KA**, Hunt DF, Shabanowitz J, Engelhard VH, Riddell SR, and Warren EH. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. *Blood*. 2006 Jan 3; [Epub ahead of print]
 156. Boyiadzis M and **Foon KA**. Natural killer cells: from bench to cancer therapy. *Expert Opin Biol Ther*. 2006 Oct; 6(10):967-970.
 157. Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, **Foon KA**, Bhattacharya-Chatterjee M. Antitumor immunity induced by anti-idiotype antibody mimicking human Her-2/neu. *Breast Cancer Res treat*. 2006 Sep 27; [Epub ahead of print]

2. Reviews, invited published papers, proceedings of conference and symposia, monographs, books and book chapters.

1. Cline MJ, Fitchen JH, **Foon KA** and Billing RJ: Antigenic characteristics of normal and malignant hematopoietic cells. Potential use of antigenic differences in cell separation and marrow transplantation. *Exp Hematol* 7(Suppl 5):246-251, 1979.
2. **Foon KA**, Fitchen JH, Billing RJ, Belzer MB, Wells JR, Golde DW, Gale RP and Cline MJ: Hematopoietic stem cell antigens. In: *Biology of Bone Marrow Transplantation*. ICN-UCLA Symposia on Molecular and Cellular Biology, Vol. XVII, RP Gale and CF Fox (eds). Academic Press, New York, 1980, pp 477-490.
3. Billings, RJ, Wells JR, Gale RP, **Foon KA**, Linker-Israeli M, Deng C, Terasaki PI and Cline MJ: *In vitro* treatment of bone marrow with heteroantisera prior to transplantation. In: *Biology of Bone Marrow Transplantation*, ICN-UCLA Symposia on Molecular and Cellular Biology, Vol. XVII, RP Gale and CF Fox (eds). Academic Press, New York, 1980, pp 167-174.

4. **Foon KA** and Fitchen JH: Antigenic structure of hematopoietic stem cells. In: *Fetal Liver Transplantation: Current Concepts and Future Directions*, GL Lucareli, TM Fliedner and RP Gale (eds). Excerpta Medica, Amsterdam, 1980, pp 167-174.
5. **Foon KA** and Billing RJ: Immunologic classification of the lymphoid leukemias: A probe for normal lymphoid differentiation. *UCLA Cancer Ctr Bull* 7:5-8, 1981.
6. Ciccarelli JC, **Foon KA** and Terasaki PI: Leukocyte antigens. In: *Methods in Hematology*, MJ Cline (ed). Churchill-Livingston, 1981, pp 84-108.
7. **Foon KA** and Costea N: Acquired hemolytic anemias. In: *Internal Medicine*, JH Stein (ed). Little, Brown and Co., Boston, 1982, pp 1564-1571.
8. Gale RP and **Foon KA**: Chronic myeloproliferative disorders. In: *Internal Medicine*, JH Stein (ed). Little, Brown and Co., Boston, 1982, pp 1632-1638.
9. Gale RP, **Foon KA**, Yale C and Zighelboim J: Immunotherapy of acute myelogenous leukemia using corynebacterium parvum and leukemia cells. In: *Immunotherapy of Human Cancer*, WD Terry and SS Rosenberg (eds). Elsevier North Holland, Inc., New York, 1982, pp 39-43.
10. Gale RP, Levine A, Golde DW, Bloomfield C and **Foon KA**: Chronic leukemias. In: *Hematology*, JR McArthur and RS Hillman (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1982, pp. 8-14.
11. **Foon KA** and Gale RP: Therapy of acute myelogenous leukemia. In: *Cancer Chemotherapy I*, FM Muggia (ed). Martinus Nijhoff Publishers, 1983, pp 303-331.
12. **Foon KA** and Gale RP: Treatment of elderly patients with acute myelogenous leukemia. *Geriatr Med Today* 2:48-61, 1983.
13. Gale RP, Levine A, Champlin R, Bloomfield C and **Foon KA**: Chronic leukemias. In: *Hematology*, JR McArthur and RS Hillman (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1983, pp 16-24.
14. Oldham RK, Sherwin SA, Maluish A, Long CW, Watson T and **Foon KA**: A phase I trial of immune interferon: A preliminary report. In: *Thymic Hormones and Lymphokines*, Goldstein AL (ed). Plenum Press, 1983.
15. **Foon KA**, Schroff RW, Mayer D, Sherwin SA, Oldham RK, Bunn PA and Hsu S-M: Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: Preliminary observations. In: *Monoclonal Antibodies and Cancer*, BD Boss, RE Langman, IS Trowbridge and R Dulbecco (eds). Academic Press, New York, 1983, pp 39-52.

16. **Foon KA**, Abrams PG, Rossio JL, Knost JA and Oldham RK: Human hybridomas: Comparison of human cell lines for production of human hybridomas and development of human hybridomas producing antigen-specific IgG using *in vitro* immunized peripheral blood cells as fusing partners. In: *Monoclonal Antibodies and Cancer*, BD Boss, RE Langman, IS Trowbridge and R Dulbecco (eds). Academic Press, New York, 1983, pp 143-155.
17. **Foon KA**, Sherwin SA, Bunn PA, Longo D and Oldham RK: Recombinant leukocyte A interferon in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and mycosis fungoides. In: *Interferon: Research, Clinical Application and Regulatory Consideration*, KC Zoon, PD Noguchi and TY Liu (eds). Elsevier Science Publishing Company, Inc., New York, 1984, pp 219-227.
18. **Foon KA** and Gale RP: Acute myelogenous leukemia: Recent advances in diagnosis and therapy. In: *Contemporary Hematology-Oncology*, Vol. 3. AS Gordon, J LoBue and R Silber (eds). Plenum Publishing Corp., New York, 1984, pp 171-214.
19. **Foon KA** and Gale RP: Acute myelogenous leukemia: Current status of therapy in adults. In: *Recent Results in Cancer Research*, Vol. 93, E Thiel and S Thierfelder (eds). Springer-Verlag, Berlin, Heidelberg, New York, 1984, pp 216-239.
20. Oldham RK, Thurman GB, Talmadge JE, Stevenson HC and **Foon KA**: Lymphokines, monoclonal antibody, and other biological response modifiers in the treatment of cancer. *Cancer* 54:2795-2806, 1984.
21. Oldham RK, **Foon KA**, Sherwin SA and Rudnick S: New biological approaches in the treatment of cancer (booklet). Am Soc Clin Oncol Educational Symposium and Educational Workshop, Bostrom Management Corp., 1984, pp 33-46.
22. Morgan AC, Pavanarasivan G, Hwang KM, Woodhouse CS, Schroff RW, **Foon KA** and Oldham RK: Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen. In: *Protides of the Biological Fluids*, H Peeters (ed). Permagon Press, Oxford, New York, 1984, pp 773-777.
23. **Foon KA** and Schroff RW: Monoclonal antibodies in cancer therapy: The NCI-BRMP experience. *Clin Immunol Today* 11:1-3, 1984.
24. Levine AM, **Foon KA** and Portlock C: Non-Hodgkin's lymphoma. In: *Hematology*, DI Feinstein and JR McArthur (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1984, pp 19-23.
25. **Foon KA** and Schroff RW: The uses of monoclonal antibodies in the diagnosis and treatment of leukemia and lymphoma. In: *In Vitro Monograph*, No. 5. 1984, pp 169-188.
26. Zighelboim J, **Foon KA**, Gale RP and Haskell CM: Acute myelogenous leukemia. In: *Cancer Treatment*, CM Haskell (ed). WB Saunders Co., Philadelphia, 1985, pp 594-705.

27. **Foon KA** and Bottino GC: Immunology of acute leukemia. In: *Neoplastic Diseases of the Blood*, PH Wiernik, G Cannellos, R Kyle and C Schiffer (eds). Churchill Livingstone, New York, 1985, pp 219-247.
28. **Foon KA**: Treatment of leukemia and lymphoma with biological response modifiers. In: *Biology and Therapy of Acute Leukemia*, L Baker, F Valeriote and V Ratanatharathorn (eds). Martinus Nijhoff, Boston, 1985, pp 213-229.
29. **Foon KA**: Biological approaches to the therapy of lymphoproliferative diseases. In: *Lymphoproliferative Diseases: Pathogenesis, Diagnosis and Therapy*, PK Pattengale, RJ Lukes and CR Taylor (eds). Martinus Nijhoff Publishers, Boston, 1985, pp 152-170.
30. Bunn PA, **Foon KA**, Ihde DC, Longo D, Schroff RW, Minna JD, Carrasquillo J, Keenan A, Larson S and Glatstein E: Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody. In: *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*, F Cavalli, G Bonadonna and M Rozencweig (eds). Martinus Nijhoff Publishers, Boston, 1985, pp 579-590.
31. Gale RP and **Foon KA**: Therapy of acute myelogenous leukemia. In: *Leukemia: Recent Advances in Biology and Treatment*, RP Gale and DW Golde (eds). Alan R. Liss, Inc., New York, 1985, pp 609-649.
32. **Foon KA** and Gale RP: Recent advances in biology and treatment of chronic lymphocytic leukemia. In: *Leukemia: Recent Advances in Biology and Treatment*, RP Gale and DW Golde (eds). Alan R. Liss, New York, 1985, pp 675-714.
33. Bunn PA Jr and **Foon KA**: Therapeutic options in advanced cutaneous T-cell lymphomas: A role for interferon alpha-2a (Roferon β -2A), Semin Oncol 12(Suppl 5):25-29, 1985.
34. Levine AM, **Foon KA** and Horning S: Non-Hodgkin's lymphoma In: *Hematology*, DI Feinstein and JR McArthur (eds). Charles B. Slack, Inc., Thorofare, New Jersey, 1985, pp 24-28.
35. **Foon KA**, Schroff RW and Gale RP: Surface markers on leukemia and lymphoma cells: Recent advances. Leucemie e Linfomi, Diagnosi e Terapia, C.E.A., Casa Editrice Ambrosiana - Milano, 1985, pp 205-229.
36. Abrams PG, Morgan AC, Schroff CJ and **Foon KA**: Monoclonal antibody studies in melanoma. In: *Monoclonal Antibodies and Cancer Therapy*, R Reisfeld and K Sell (eds). UCLA Symposium on Molecular and Cellular Biology. Alan R. Liss, New York, 1985, pp 233-236.
37. *Monoclonal Antibody Therapy of Human Cancer*, **Foon KA** And Morgan AC (eds). Martinus Nijhoff Publishing, Boston, 1985.

38. Morgan AC and **Foon KA**: Monoclonal antibody therapy of cancer: Pre-clinical models and investigations in man. In: *Basic and Clinical Tumor Immunology*, RB Herberman (ed). Martinus Nijhoff Publishers, Boston, 1986, pp 177-200.
39. **Foon KA**, Schroff RW and Bunn PA: Monoclonal antibody therapy for patients with leukemia and lymphoma. In: *Monoclonal Antibody Therapy of Human Cancer*, KA Foon and AC Morgan (eds). Martinus Nijhoff Publishers, Boston, 1986, pp 85-101.
40. **Foon KA** and Gale RP: Principles of leukemia treatment. In: *Leukemia Therapy*, RP Gale (ed). Blackwell Scientific Publications, Inc., Boston, 1986, pp 1-23.
41. Gale RP and **Foon KA**: Therapy of acute myelogenous leukemia. In: *Leukemia Therapy*, RP Gale (ed). Blackwell Scientific Publications, Inc., Boston, 1986, pp 99-145.
42. **Foon KA** and Gale RP: Therapy of chronic lymphocytic leukemia. In: *Leukemia Therapy*, RP Gale (ed). Blackwell Scientific Publications, Inc., Boston, 1986, pp 165-180.
43. Abrams PG, Morgan AC, Schroff RW, Woodhouse CS, Carrasquillo J, Stevenson HC, Fer MF, Oldham RK and **Foon KA**: Localization and biodistribution studies of a monoclonal antibody in patients with melanoma. In: *Monoclonal Antibodies and Cancer Therapy*, R Reisfeld and K Sell (eds). Alan R. Liss, New York, 1986, pp 233-236.
44. **Foon KA** and Morgan AC: Monoclonal antibody therapy of cancer: Animal models and human trials. In: *Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment*, JA Roth (ed). Futura Publishing Co., Mount Kisko, NY, 1986, pp 141-171.
45. Stevenson HC, **Foon KA** and Sugarbaker PH: *Ex vivo* activated monocytes and adoptive immunotherapy trials in colon cancer patients. In: *Transfusion Medicine: Recent Technological Advances*. Alan R. Liss, New York, 1986, pp 75-82.
46. **Foon KA**, Schroff RW and Bunn PA: Clinical applications of monoclonal antibodies in patients with leukemia and lymphoma. In: *Transfusion Medicine: Recent Technological Advances*, K Murawski and F Peetoom (eds). Alan R. Liss, Inc., New York, 1986, pp 265-284.
47. **Foon KA**: Interferon therapy of the lymphoproliferative disorders. Semin Hematol 23(Suppl 1):10-13, 1986.
48. **Foon KA**: Biological therapy of cancer. Breast Cancer Res Treat 7:5-14, 1986.
49. Gale RP and **Foon KA**: Acute myeloid leukemia: Recent advances in therapy. Clin Hematol 15:781-810, 1986.
50. **Foon KA**, Gale RP and Todd RF III: Recent advances in the immunologic classification of leukemias. Semin Hematol 23:257-283, 1986.

51. **Foon KA**, Order SE and Rosenberg SA: *Role of Biologics in Cancer Treatment*, Am Soc Clin Oncl, Educational Booklet, Bostrom Corp., Chicago, 1986, pp 19-27.
52. **Foon KA** and Bunn PA Jr: Alpha interferon treatment of cutaneous T-cell lymphoma and chronic lymphocytic leukemia. *Semin Oncol* 13(Suppl 5):35-39, 1986.
53. **Foon KA**, Roth MS and Bunn PA Jr: Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphoma, cutaneous T-cell lymphoma and chronic lymphocytic leukemia. *Semin Oncol* 13(Suppl 2):35-42, 1986.
54. Golomb HM, **Foon KA** and Parkinson DA: Biologic response modifiers. In: Hematology. 1986, pp 64-70.
55. **Foon KA** and Gale RP: Principles of leukemia treatment. In: Leukemia, JA Whittaker and IW Delamore (eds). Blackwell Scientific Publications, Ltd., Osney Mead, Oxford, 1987, pp 270-285.
56. **Foon KA** and Gale RP: Immunologic classification of lymphoma and lymphoid leukemias. *Blood Rev* 1:77-88, 1987.
57. **Foon KA** and Gale RP: Therapy of chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, RP Gale and K Rai (eds). Alan R. Liss, Inc., New York, 1987, pp 307-316.
58. **Foon KA**, Roth MS and Gale RP: Biological therapy of chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Directions, RP Gale and K Rai (eds). Alan R. Liss, Inc., New York, 1987, pp 353-366.
59. Steis RG, **Foon KA** and Longo DL: Current and future uses of recombinant alpha-interferon in the treatment of low-grade non-Hodgkin's lymphoma. *Cancer* 59(Suppl):658-663, 1987.
60. **Foon KA** and Gale RP: Staging and therapy of chronic lymphocytic leukemia. *Semin Hematol* 24:264-274, 1987.
61. Gale RP and **Foon KA**: Biology of chronic lymphocytic leukemia. *Semin Hematol* 24:209-229, 1987.
62. **Foon KA**, Roth MS and Bunn PA Jr: Interferon therapy of non-Hodgkin's lymphoma. *Cancer* 59(Suppl):601-604, 1987.
63. Roth MS and **Foon KA**: Current status of interferon therapy in oncology. *Prog Hematol* XV, 19-38, 1987.

64. Sherwin SA, **Foon KA** and Oldham RK: Animal tumor models for biological response modifier therapy: An approach to the development of monoclonal antibody therapy in humans. In: *Fundamentals of Cancer Chemotherapy*, K Hellman and S Carter (eds). McGraw-Hill Book Co., 1987, pp 202-211.
65. Golomb HM, **Foon KA** and Parkinson DA: Biologic response modifiers. In: *Hematology*. 1987, pp 69-76.
66. Gale RP and **Foon KA**: Therapy of acute myelogenous leukemia. *Semin Hematol* 24:40-54, 1987.
67. Bunn PA, Ihde PC and **Foon KA**: Recombinant interferon alpha-2a, an active agent in advanced cutaneous T-cell lymphomas. *Int J Cancer (Suppl 1)*:9-13, 1987.
68. Roth MS and **Foon KA**: Biotherapy with interferon in hematologic malignancies. *Oncol Nurs* 14(Suppl 6):16-22, 1987.
69. Roth MS and **Foon KA**: Interferon: Biology and therapy in human cancer. In: *Immunology in New Drug Development*, J Sinkule (ed). Pergamon Books, Inc., Elmsford, NY, 1987.
70. **Foon KA**: Biological approaches to cancer therapy. In: *Modern Trends in Human Leukemia VII*, R Neth, RC Gallo, MF Greaves and H Kabisch (eds). Springer-Verlag, Berlin, 1987, pp 103-109.
71. **Foon KA**: Advances in cancer: Monoclonal antibody therapy of hematologic malignancies. *New Jersey Medicine* 84:269-274, 1987.
72. **Foon KA** and Gale RP: Interferon in chronic lymphocytic leukemias and herpes zoster infections in leukemia patients. In: *Clinical Aspects of Interferon*, M Revel (ed). Martinus Nijhoff Publishing, Boston, 1988, pp 141-148.
73. Roth MS and **Foon KA**: Clinical aspects of interferon therapy in human cancer. In: *Cytotoxic Lymphokines and Cancer: Biological and Chemical Aspects*, JH Ranson and J Ortaldo (eds). Humana Press, 1988, pp 247-271.
74. **Foon KA**, Gale RP and Todd R III: Immunological classification of lymphoma and lymphoid leukemias. In: *Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, JM Bennett and KA Foon (eds). Martinus Nijhoff Publishing, Boston, 1988, pp 1-30.
75. Roth MS, Bunn PA and **Foon KA**: Interferon therapy for lymphoproliferative disorders. In: *Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, JM Bennett and KA Foon (eds). Martinus Nijhoff Publishing, Boston, 1988, pp 231-252.

76. Kaminski MS and **Foon KA**: Monoclonal antibody therapy of lymphomas and leukemias. In: *Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, JM Bennett and KA Foon (eds). Martinus Nijhoff Publishing, Boston, 1988, pp 253-263.
77. **Foon KA**, Gale RP and Todd RF III: Immunologic classification of leukemia. In: *Leukemia*, AM Mauer (ed). Johns Hopkins University Press, Baltimore, 1988.
78. **Foon KA**: Advances in immunotherapy of cancer: Monoclonal antibodies and interferon. Semin Nurs Oncol 4:112-119, 1988.
79. Mitchell MS and **Foon KA**: Lymphokines. Immunol Allergy Clin North Am 8:121-135, 1988.
80. Abrams DI, **Foon KA** and Gold JW: Lymphadenopathy: A diagnostic plan. Patient Care, 4:95-112, 1988.
81. **Foon KA** and Casciato DA: Chronic leukemias. In: *Manual of Clinical Oncology*, DA Casciato and BB Lowitz (eds). Little, Brown and Co., Boston, 2nd Edition, 1988, pp 360-375.
82. **Foon KA** and Casciato DA: Chronic leukemias. In: *Manual of Clinical Oncology*, DA Casciato and BB Lowitz (eds). Little, Brown and Co., Boston, 2nd Edition, 1988, pp 386-400.
83. **Foon KA**: Biotherapy of cancer with interleukin-2, colony stimulating factors, and monoclonal antibodies. Nurs Forum 15:(6):13-22, 1988.
84. **Foon KA** and Gale RP: Chronic lymphocytic leukemia and related diseases. In: *Recent Advances in Haematology 5*, AV Hoffbrand (ed). Churchill-Livingston, London, 1988, pp 179-209.
85. Gale RP and **Foon KA**: Biology of chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia*, A Polliack and D Catovsky (ed). Harwood Acad, Switzerland, 1988, pp 263-287.
86. **Foon KA** and Gale RP: Staging and therapy of chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia*, A Polliack and D Catovsky (eds). Harwood Acad, Switzerland, 1988, pp 139-158.
87. **Foon K** and Gale RP: Clinical transformation of chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:385-388, 1988.
88. *Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*, Bennett JM and **Foon KA** (eds). Martinus Nijhoff Publishing, Boston, 1988.

89. **Foon KA** and Gale RP: Chemotherapy of acute myelogenous leukemia. In: *Bone Marrow Transplantation*. Alan R. Liss, New York, 1989, pp 75-94.
90. **Foon KA**: Laboratory and clinical applications of monoclonal antibodies for leukemias and non-Hodgkin's lymphomas. *Curr Probl Cancer* 13:57-128, 1989.
91. Gale RP and **Foon KA**: The chronic leukemias. In: *Conn's Current Therapy*, RE Rakel (ed). WB Saunders Co., 1989, pp 376-384.
92. Vaickus L and **Foon KA**: Role of monoclonal antibodies in oncology. Hospital Formulary. The P & T Committee Journal 24:704-710, 1989.
93. **Foon KA**, Champlin RE and Gale RP: Acute myelogenous leukemia and the myelodysplastic syndromes. In: *Cancer Treatment*, CM Haskell (ed). WB Saunders Co., Philadelphia, 3rd Edition, pp 589-606, 1990.
94. Vaickus L and **Foon KA**: Clinical application of monoclonal antibodies in oncology. Hospital Formulary. The P & T Committee Journal 25(1):50-56, 1990.
95. **Foon KA** and Gale RP: The chronic leukemias. In: *Conn's Current Therapy*, RE Rakel (ed). WB Saunders Co., pp 363-373, 1990.
96. Vaickus L and **Foon KA**: Commentary: Monoclonal antibody therapy of lymphoproliferative disorders. *Oncology* 4(3):90, 1990.
97. **Foon KA** and Gale RP: Alternate first-line treatment for acute myelogenous leukemia. In: *Acute Myelogenous Leukemia: Progress and Controversies*. Wiley Liss, Inc., pp 353-361, 1990.
98. **Foon KA** and Fanning J: Immunotherapy of gynecologic malignancies. *Semin Surg Oncol* 6:364-368, 1990.
99. **Foon KA** and Gale RP: Chronic lymphoid leukemias. In: *Blood: Principles and Practice of Hematology*, RI Handin, SE Lux and TP Stossel (Eds). JB Lippincot and Co., Philadelphia, 1990.
100. **Foon KA**, Champlin RE and Gale RE: Therapy of acute lymphoblastic leukemia. UCLA Symposium. In: *Acute Lymphoblastic Leukemia*, Vol. 108, pp 157-196, 1990.
101. Vaickus L and **Foon KA**: Biological therapies of lymphomas. In: *Malignant Lymphoma: Biology, Diagnosis and Treatment*, CW Erber, S Flecknoe-Brown and M Garson (eds), pp 177-198, 1991.
102. Vaickus L and **Foon KA**: Immunology of acute leukemia. In: *Neoplastic Diseases of the Blood*, PH Wiernik, GP Canellos, RA Kyle and CA Schiffer (eds), 2nd Edition. Churchill-Livingstone, New York, pp 183-214, 1991.

103. Vaickus L and **Foon KA**: Overview of monoclonal antibodies in the diagnosis and therapy of cancer. *Cancer Invest* 9(2):195-210, 1991.
104. Bhattacharya-Chatterjee M, **Foon KA** and Köhler H: Anti-idiotype monoclonal antibodies as vaccines for human cancer. *Int Rev Immunol* 7(4):289-302, 1991.
105. **Foon KA**, Chronic Lymphocytic Leukemia. *Cortlandh Forum*, July 1992, 160-163.
106. Bhattacharya-Chatterjee M, **Foon KA** and Köhler H: Anti-idiotype approaches to cancer therapy. *Contemp Oncology* 2:27-36, 1992.
107. Köhler, H, Müller S, Chatterjee M and **Foon KA**. Therapeutic anti-clonotypic antibodies. *Proceed. 8th Internat'l. Congress Immunol.*, Springer Verlag, p. 619-626, 1992.
108. Stickney D, **Foon KA**: Biological Response Modifiers: Therapeutic Approaches to Lymphoproliferative Diseases. *Current Opinion in Oncology* Oct;4(5):847-855, 1992.
109. Biddle WC and **Foon KA**: Monoclonal antibodies in therapy, alone or conjugated with drugs. Review chapter for inclusion in: *The Biomodulation of Cancer*, Malcolm M (ed). McGraw-Hill, Inc., pp 207-251, 1992.
110. **Foon KA**, Robbins BA, Ellison DJ and Vaickus L: Immune surface markers in lymphoproliferative disorders. *Adv Leuk Lymphoma* 3:3-11, 1992.
111. Vaickus L, Ball ED and **Foon KA**: Immunologic classifications of leukemias. In: *Clinical Cancer Markers: Diagnosis, Prognosis and Monitoring*, S Sell (ed). Humana Press, 1992.
112. Vaickus L and **Foon KA**. In: *Leukemia. Encyclopedia of Science and Technology*, 7th Edition. McGraw-Hill Book, New York, 1992.
113. Schiller GJ, **Foon KA** and Gale RP: Principles of leukemia treatment. In: *Leukemia*, Whittaker JA (ed), 2nd Edition. Blackwell Scientific Publications, Ltd., pp 329-354, 1992.
114. **Foon KA** and Gale RP: Therapy of acute myelogenous leukemia. *Blood Rev* 6:15-25, 1992.
115. Bloomfield CD, **Foon KA** and Levine EG: Leukemias. In: *Medical Oncology*, Calabrese T and Schein PS (eds). Pergamon Press, New York, pp. 459-502, 1993.
116. **Foon KA**, Rai KR and Gale RP: Chronic lymphocytic leukemia. In: *Hematology Clinical and Laboratory Practice*, Bick RL (ed). Mosby, St. Louis, pp. 803-815, 1993.
117. **Foon KA** and Gale RP: Cutaneous T-cell lymphoma. In: *Hematology Clinical and Laboratory Practice*, Bick RL (ed). Mosby, St. Louis, pp. 841-844, 1993.

118. **Foon KA.** Clinical simulations in the management of Chronic Lymphocytic Leukemia *Medical Age Publishing*, Norwalk, Connecticut, p. 1-15, 1993.
119. **Foon KA** and Chatterjee M: Anti-idiotype antibodies: novel therapeutic approaches to cancer therapy. In: *Tumor Immunology: Basic Mechanism and Prospects for Therapy*. Goldfarb/Whiteside (Eds.), Marcel Dekker, Inc., New York, N.Y., Chapter 23, p. 281-292, 1993.
120. Chatterjee M, Mrozek E, Vaickus L, Oseroff A, Stoll H, Russel D, Köhler H and **Foon KA.** Anti-idiotype (Ab2) vaccine therapy for cutaneous T cell lymphoma (CTCL). *Ann NY Acad Sci* Aug 12;690:376-378, 1993.
121. **Foon KA.** The Cytokine Network. *Oncology Supp*, 7(12), pp. 11-15, 1993.
122. **Foon KA** and Bhattacharya-Chatterjee M. *Anti-Idiotype Antibodies: Novel Therapeutic Approach to Cancer Therapy*. Marcel Dekker, Inc., 1994.
123. Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Köhler H, **Foon KA.** Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. *Adv Exp Med Biol* 353:139-48, 1994.
124. **Foon KA**, Bhattacharya-Chatterjee M. Anti-idiotype antibodies: novel therapeutic approach to cancer therapy. *Immunol Ser* 61:281-92, 1994.
125. Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Kohler H and **Foon KA.** Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer. In: *Proceed 5th Inter. Conf. on Breast Cancer Therapy & Immunology*, RL Ceriani (Ed.), Plenum Press, NY., 139-148, 1994.
126. **Foon KA** and Fisher RI. Lymphomas. In: *Williams Hematology*, Fifth Edition (Eds. EP Beutler, MA Lichtman, BS Coller and TJ Kipps), McGraw-Hill, Inc., 1995.
127. Köhler H, Bhattacharya-Chatterjee M, Muller S and **Foon KA.** Idiotype Manipulation in Disease Management. In: *Immunobiology of Proteins and Peptides*, Eighth Edition (Eds. M. Zouhair Atassi and G. Bixler, Jr.), Arizona Plenum Press, Proceedings of the Annual Symposium on Immunobiology of Proteins and Peptides, New York. *Adv Exp Med Biol* 383:117-122, 1995.
128. John WJ and **Foon KA.** *Clinical Applications of Interferon in Other Tumors*. J.B Lippincott Co, Philadelphia, 1995.
129. Chakraborty M, **Foon KA**, Köhler H, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen. *J Immunother Emphasis Tumor Immunol* 18:95-103, 1995.
130. **Foon KA.** Chronic lymphoid leukemias: Recent advances in biology and therapy. *Stem Cells* 13:1-21, 1995.

131. Bhattacharya-Chatterjee M, Kohler H and **Foon KA**. Idiotypes in cancer. In: *Idiotypes in Medicine - Infections, Autoimmunity and Cancer*. Shoenfeld/Ferrone/Kennedy (Eds), Elsevier Science, Amsterdam, The Netherlands, B.V. pp. 441-453, 1997.
132. **Foon KA**. Interferon therapy of hematologic malignancies. In: *Cancer Treat Res*. 94:1-21, 1998.
134. John WJ and **Foon KA**. Interferon use in solid tumors. In: *Cancer Treat Res*. 94:23-33, 1998.
135. *Biological and Hormonal Therapies of Cancer*, **Foon K.A.**, Muss HB (Eds), Kluwer Academic Publishers, MA, USA, 1998.
136. **Foon KA**. Chronic lymphoid leukemias. In: *Manual of Clinical Hematology*. Little Brown & Co., Boston, M.A. pp. 461-478, 2000.
137. **Foon KA** and Casciato DA. Acute leukemia. In: *Manual of Clinical Oncology* (Ed. Casciato DA), Little Brown & Co., Boston, M.A. pp. 496-513, 2000.
138. Bhattacharya-Chatterjee M and **Foon KA**. Anti-idiotype antibody vaccine therapies of cancer. In: *Cancer Treat Res*. 94:51-68, 1998.
139. **Foon KA** and Casciato DA. Chronic leukemias. In: *Manual of Clinical Oncology* (Ed. Casciato DA), Little Brown & Co., Boston, M.A. Fourth Ed. pp. 461-478, 2000.
140. **Foon KA**, Fisher RI. Lymphomas. In: *Williams Hematology*, Sixth Edition (Eds. EP Beutler, MA Lichtman, BS Coller and TJ Kipps), McGraw-Hill, Inc., 1999.
141. Bhattacharya-Chatterjee M, Chakraborty M, Chatterjee SK, John WJ and **Foon KA**. Vaccine therapy of colorectal cancer patients with an Anti-Id Mab that mimics carcinoembryonic antigen. *Proc. 10th International Congress of Immunology*, New Delhi, India, Monduzzi, M. Editor, p. 1503-1507, 1999.
142. Chatterjee SK, Qin H-X, Tripathi PK, Deng S, Bhattacharya-Chatterjee M and **Foon KA**. Anti-carcinoembryonic antigen (CEA) immunity induced by a single chain FV format of an anti-idiotype antibody mimicking CEA. *Proc. 10th Intl. Congress of Immunology*, New Delhi, India, Monduzzi M. Editor, p. 1223-1227, 1999.
143. Arnold SM, Patchell R, Lowy AM and **Foon KA**. Paraneoplastic syndromes. In: *Principals and Practices of Oncology*, Fifth Edition (Eds. VT DeVita, S Hellman, and SA Rosenberg), J.B. Lippincott Co., 46:2397-2422, 1997.
144. **Foon KA** and LaRocca RV. Sequential therapy with fludarabine followed by

cyclophosphamide, mitoxantrone, vincristine and prednisone: effective therapy for follicle enter lymphomas, follicular grades I and II. In: *Purine Analogues*, June Vol. 2, No.1, 1999.

146. **Foon KA.** Monoclonal antibodies in the treatment of lymphomas for the year 2000. In: *Cancer: Principles and Practice of Oncology*, May Vol. 14, No. 4, 2000.
147. **Foon KA.** Monoclonal antibodies: basic principles, basic concepts and antigens recognized. *Principles and Practice of Oncology*, 3rd Edition, Section 14.1, pp371-381, 2000.
148. **Foon KA.** Basic concepts and antigens recognized, In: *Principles and Practice of the Biologic Therapy of Cancer*, 3rd Edition, Monoclonal Antibodies: Basic Principles, Section 14.1, pp371-381, 2000 .
149. Bhattacharya-Chatterjee M, Nath Baral R, Chatterjee SK, Das R, Zeytin H, Chakraborty M, and **Foon KA.** Counterpointe. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. *Cancer Immunol Immunother* 49:133-141, 2000.
150. Bhattacharya-Chatterjee M, Chatterjee SK and **Foon KA.** Anti-idiotype vaccine against cancer. *Immunol Lett* 74:51-58, 2000.
151. **Foon KA.** Monoclonal antibody therapies for lymphomas. *The Cancer Journal* 6:273-278, 2000.
152. Bhattacharya-Chatterjee M, Chatterjee SK and **Foon KA.** The Anti-idiotype vaccines for immunotherapy. *Current Opinions in Molecular Therapeutics*, 3:63-39, 2001.
153. **Foon KA.** Immunotherapy for colorectal cancer. *Current Oncology Reports* Mar;3:116-126, 2001.
154. Safa MM and **Foon KA.** Adjuvant immunotherapy for melanoma and colorectal cancers. *Seminars in Oncology* 28:68-92, 2001.
155. **Foon KA** and Bhattacharya-Chatterjee M. Cancer vaccines. In Encyclopedic References Of Cancer, Springer-Verlag, Heidelberg, Germany, 152-157, 2001.
156. **Foon KA** and Bhattacharya-Chatterjee M. GI cancer management: biological therapy. In: *Gastrointestinal Oncology: Principles and Practices*. Kelsen DP/Daly JM/Kern SE/Levin B/Tepper JE (Eds.) Lippincott Williams & Wilkins, UK, Nov. 2001.
157. Bhattacharya-Chatterjee M, Chatterjee SK and **Foon KA.** Anti-idiotype antibody vaccine therapy for cancer. *Expert Opin. Biol. Ther.* 2 (8); 869-881, 2002.

158. Bhattacharya-Chatterjee M, **Foon KA**. Tumor markers and immunotherapy of cancer. In: *Clinical Immunology*. PC Sen Gupta (Ed), Oxford University Press; Jan 9, 2003; Vol.1, Part A: Basic Immunology: Chapter 13.
159. **Foon KA**. Cancer Vaccines. *Schwab: Encyclopedic Reference of Cancer*, Deutsches Krebsforschungszentrum, Heidelberg, Germany. (in press).
160. Casciato DA, Agha ME, **Foon KA**. Acute Leukemia and Myelodysplastic Syndromes In: *Manual of Medical Oncology*, Casciato DA (Ed.), Lippincott, Williams & Wilkins, Philadelphia, 2004, 5th Edition, Chapter 25, pp. 514-533.
161. **Foon KA** and Casciato DA. Chronic Leukemias In: *Manual of Medical Oncology*. Casciato DA (Ed.), Lippincott, Williams & Wilkins, Philadelphia, 2004, 5th Edition, Chapter 23, pp. 480-495.
162. **Foon KA**, Ghobrial I, Geskin LJ, and Jacobs SA: The Non-Hodgkin Lymphomas. In: *Williams Hematology*. Lichtman/Beutler/Kaushansky/Kipps/SilgsohnPrchal (Eds.P), McGraw-Hill, 7th Edition, Chapter 96 (in press, 2005).
163. **Foon KA**. Biological Therapies: Twenty-Five Years of Progress in Cancer Therapy. *Cancer Biol Ther*. 2006 Mar; 5(3):331-4. Epub 2006 Mar 20.
164. Boyiadzis M, **Foon KA**, and Herberman RB. NK Cells in Cancer Immunotherapy: Three Decades of Discovery. *Discov Med*. 2006 Dec; 6(36):243-8.

3. Published Abstracts

1. **Foon KA**, Wahl SM, Rosenstreich DL and Oppenheim JJ: Serotonin (5-hydroxy-tryptamine) induced lymphokine production from human peripheral blood lymphocytes. *Fed Proc* 34:1010, 1975.
2. **Foon KA**, Sher NA and Fishman ML: Macrophage chemotactic factor and migration inhibition factor in the aqueous humor during experimental uveitis. *Fed Proc* 35:492, 1976.
3. **Foon KA**, Naeim F and Gale RP: Acute myelogenous leukemia (AML): Morphologic subclass and response to therapy. *Blood* 52(Suppl 1):249, 1978.
4. Gale RP, Zighelboim J, **Foon KA** and Cline JJ: Intensive chemoimmunotherapy in acute myelogenous leukemia (AML). *Blood* 52(Suppl 1):250, 1978.
5. Naeim F, Zighelboim J, **Foon KA**, Gale RP and Walford RL: Acute myelogenous leukemia and HLA-DR antigens. *Blood* 52(Suppl 1):226, 1978.

6. **Foon KA**, Fitchen JH, Billing RJ, Belzer M and Cline MJ: Antigenic characteristics of human hematopoietic progenitor cells: Potential use in bone marrow transplantation. Proceedings of the Conference on Aplastic Anemia. HIH Publication No. 81-1008:294 1981.
7. **Foon KA**, Naeim F, Saxon A, Stevens R and Gale RP: Helper T-lymphocyte leukemia with clinicopathologic features similar to hairy cell leukemia. Blood (Suppl 1):187a, 1979.
8. **Foon KA**, Billing R, Belzer M, Fitchen J, Drew I and Terasaki P: A myeloid antigen defined by a heteroantiserum. Blood (Suppl 1):109a, 1979.
9. **Foon KA**, Billing RJ, Terasaki P and Cline MJ: Immunologic classification of acute lymphoblastic leukemia: Implications for normal lymphoid maturation. Blood (Suppl 1):186a, 1979.
10. Belzer M, Fitchen JH, **Foon KA** and Golde D: Monoclonal Ia-like (DR) antibody does not inhibit erythroid colony formation. Blood (Suppl 1):133a, 1979.
11. **Foon KA**, Fitchen JH, Belzer MB, Golde DW and Cline MJ: Hematopoietic stem cell antigens. J Supramol Struct (Suppl 4):35, 1980.
12. **Foon KA**, Zighelboim J and Gale RP: Long-term results of intensive chemotherapy of acute myelogenous leukemia. Proc Am Soc Clin Oncol 21:361, 1980.
13. Linker-Israeli M, Billing RJ, **Foon KA**, Fitchen JH and Terasaki PI: Monoclonal antibodies reactive with acute myelogenous leukemia (AML) cells. Fed Proc 40:1118, 1981.
14. **Foon KA**, Schroff RW, Bunn PA, Cline MJ and Fahey JL: Cell surface antigens defining functional T-cell subsets in Sezary cell leukemia. Proc Am Assoc Cancer Res 22:304, 1981.
15. Schroff R, **Foon KA**, Gee T, Fillipa D and Fahey J: Simultaneous expression of T and B surface markers by a subpopulation of leukemic phase lymphoma cells. Proc Am Assoc Cancer Res 22:304, 1981.
16. **Foon KA** and Schroff RW: Unique antigen expression of plasmacytoma cells associated with T lymphocytes with a suppressor phenotype. Blood 58(Suppl 1): 166a, 1981.
17. **Foon KA**, Schroff RW and Seeger RC: A monoclonal antibody recognizing human Thy-1: Distribution on normal and malignant hematopoietic cells. Blood 58(Suppl 1):129a, 1981.
18. Sherwin S, Knost J, Fein S, Abrams P, **Foon K**, Ochs J, Schoenberger C and Oldham R: A multiple dose phase I trial of recombinant leukocyte interferon using a 3 x weekly schedule. Proc Am Soc Clin Oncol 1:35, 1982.

19. Knost J, Sherwin S, **Foon K**, Abrams P, Ochs J, Schoenberger C and Oldham R: A phase I trial of lymphoblastoid interferon using a 6-hour intravenous infusion. Proc Am Soc Clin Oncol 1:35, 1982.
20. Bernhard MI, **Foon KA**, Clarke GC, Christensen WL, Hoyer L, Key M, Hanna MG and Oldham RK: A phase I trial of lymphoblastoid interferon using a 6-hour intravenous infusion. Proc Am Soc Clin Oncol 1:35, 1982.
21. Oldham RK, Bernhard MI, Key M, Peters LC, Brandhorst J, Hanna MG and **Foon KA**: Monoclonal antibody serotherapy of solid tumors: A guinea pig model II: *In vivo* studies. 13th Intl Cancer Congress, 1982.
22. Bernhard MI, **Foon KA**, Clarke GC, Christensen WL, Hoyer L, Key M, Hanna MG and Oldham RK: Monoclonal antibody serotherapy of solid tumors: A guinea pig model I: Characterization of monoclonal antibody. First Annual Congress of Hybridoma Research, 1982.
23. Zighelboim J, **Foon K**, Yale C and Gale RP: Treatment of acute myelogenous leukemia with intensive induction and consolidation chemotherapy. Proc Am Soc Clin Oncol 1:128, 1982.
24. Mitsuyasu R, McIntyre RM, **Foon KA** and Gale RP: A new syndrome of immune deficiency, hepatitis and aplastic anemia in young males.
25. **Foon KA**, Rossio J, Schroff RW, Wahl SM, Abrams PG, Rager H, Clarke G and Fidler IJ: Human T-T hybridomas secreting lymphokines. Blood 60(Suppl 1):72a, 1982.
26. Mayer D and **Foon KA**: Nursing implications of monoclonal antibody sero therapy. 8th Oncology Nursing Society Congress Proceedings: 48, 1983.
27. Schroff RW, **Foon KA**, Bunn PA, Sherwin SA and Oldham RK: Immunologic studies of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL) patients receiving monoclonal antibody therapy. Fed Proc.
28. Schroff RW, Klein RA and **Foon KA**: Antigen modulation in chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL) patients undergoing monoclonal antibody therapy. Fed Proc.
29. **Foon K**, Rossio J, Schroff R, Abrams P, Rager H, Clarke G, Pickeral S and Fidler IJ: Human T-cell hybridomas secreting interleukin-2 (IL-2). Proc Am Assoc Cancer Res 24:220, 1983.
30. **Foon K**, Bunn P, Schroff R, Mayer D, Sherwin S, Longo D, Ochs J, Bottino G, Fer M, Herberman R and Oldham R: Monoclonal antibody therapy of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL). Proc Am Soc Clin Oncol 2:48, 1983.

31. Oldham RK, Hwang KM, Schroff RW, Pearson JW and **Foon KA**: Guinea pig hepatocarcinoma--A model for monoclonal antibody immunoconjugate testing. *Fed Proc.*
32. Fer MF, Abrams PG, Giardina S and **Foon KA**: Monoclonal antibodies in diagnostic oncology: Applications to the recognition of lung cancers. *Proc Am Assoc Cancer Res* 24:128, 1983.
33. Neubauer RH, **Foon KA**, Seeger RC and Rabin H: Monoclonal antibody reactivity with a Thy-1 determinant on normal and malignant hematopoietic cells of human and non-human primate origin. *J Immunogenet* vol.11, no. 3-4; (1984 June-Aug):233-43.
34. Oldham RK, Sherwin SA, Morgan AC, **Foon KA**, Abrams PG and Kimball ES: Monoclonal antibody (9.2.27) therapy of malignant melanoma. *Proc Am Soc Clin Oncol* 2:47, 1983.
35. Gale RP, Zighelboim J and **Foon K**: The role of maintenance chemotherapy in acute myelogenous leukemia. *3rd Intl Symp Therapy Acute Leukemias.*
36. **Foon KA**, Bunn PA, Schroff WW and Oldham RK: Monoclonal antibody therapy of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL). *Proc 5th Intl Congress of Immunology.*
37. Schroff RW, Klein RA and **Foon KA**: Enhancing effect of monocytes upon cell surface antigen modulation: Implications to the therapeutic use of monoclonal antibodies. *Proc 5th Intl Congress of Immunology.*
38. **Foon KA**, Bernhard MI, Oeltmann TN, Hoyer LC, Hanna MG and Oldham RK: Monoclonal antibodies conjugated to naturally occurring toxins. *Sym Discovery and Development of Naturally Occurring Antitumor Agents*, 1983.
39. Woodhouse CS, Schroff R, Morgan A, **Foon KA** and Oldham R: Immunohistological assessment of localization of monoclonal antibody administered for therapy of malignant melanoma. *Fed Proc*, 1984.
40. Morgan AC Jr, Woodhouse CS, Knost JA, **Foon KA** and Oldham RK: Monoclonal antibodies to human colorectal tumor-associated antigens: Improved elicitation and subclass restriction. *Third Annual Congress for Hybridoma Research, Fall*;3(3):233-45, 1984.
41. Schroff RW, Carrasquillo JA, **Foon KA**, Keenan AM, Morgan AC Jr, Bunn PA, Reynolds HC, Perentesis P, Larson SM and Abrams PG: Clinical trials of radioimmunoconjugates of monoclonal antibodies for biodistribution and tumor diagnosis. *Fed Proc*, 1984.

42. Stevenson HC, Keenan AM, Stellar P, Miller P, Beman JA, **Foon KA**, Ottow R, Larson SM and Sugarbaker P: The fate of activated blood monocytes (IMO) into the peritoneum of patients with peritoneal colorectal carcinomatosis (PCC). *Clin Res*.
43. **Foon KA**, Schroff RW, Bunn PA Jr and Oldham RK: Effects of monoclonal antibody serotherapy on patients with chronic lymphocytic leukemia (CLL). *Blood* 62(Suppl 1):202a, 1983.
44. Bunn PA, **Foon KA**, Schroff RW, Hsu SM, Longo DL, Winkler CF and Oldham RK: T101 monoclonal antibody (MoAb) therapy for T-cell lymphomas. *Blood* 62(Suppl 1):210a, 1983.
45. Sherwin S, **Foon KA**, Bunn P Jr, Longo D and Oldham R: Recombinant leukocyte A interferon in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and mycosis fungoides. *Blood* 62(Suppl 1):215a, 1983.
46. Giardina SL, Schroff RW, Abrams PG, Woodhouse C, Rager HC, Morgan AC and **Foon KA**: Generation of murine anti-idiotype monoclonal antibodies to B-cell-derived leukemias and lymphomas. *Blood* 62(Suppl 1):538, 1983.
47. Abrams PG, Giardina SL, Morgan AC, Oldham RK and **Foon KA**: The rapid generation of large quantities of human monoclonal immunoglobulins in highly concentrated nude mouse ascites: Implications for the development of murine anti-idiotype monoclonal antibodies in leukemia and lymphoma. *Blood* 62(Suppl 1):186a, 1983.
48. **Foon KA**, Maluish AE, Abrams PG, Wrightington S, Schnipper EF and Herberman RB: A phase II trial of recombinant leukocyte \square interferon (rIFN- \square) for advanced hairy cell leukemia: Therapeutic and immunologic results. *Blood* 64(Suppl 1):164a, 1984.
49. **Foon KA**, Bottino GC, Abrams PG, Fer MF, Longo DL, Schoenberger CS and Oldham RK: A phase II trial of recombinant alpha interferon (rINF- \square) for advanced chronic lymphocytic leukemia (CLL). *Blood* 64(Suppl 1):164a, 1984.
50. Oldham R, Woodhouse C, Schroff R, Abrams P, Fer M, Kimball E, **Foon KA** and Morgan AC: Monoclonal antibody therapy of malignant melanoma: *In vivo* localization in cutaneous metastasis after intravenous administration. *Proc Am Soc Clin Oncol* 3:65, 1984.
51. Fer MF, Beman J, Stevenson HC, Maluish A, Moratz C, **Foon KA**, Herberman RB, Oldham RK with Terman DS, Young JB and Daskal IR: A trial of autologous plasma perfused over protein A in patients with breast cancer. *Proc Am Soc Clin Oncol* 3:63, 1984.
52. Bunn P, **Foon KA**, Ihde D, Longo D, Winkler C, Zeffren J, Oldham R and Sherwin S: Recombinant leukocyte a interferon (IFL-rA) in the treatment of advanced refractory cutaneous T-cell lymphomas (CTCL). *Proc Am Soc Clin Oncol* 3:52, 1984.

53. Ruscetti F, Faltynek C, Abe H and **Foon K**: B-cell growth factor initiated lines from patients with hairy cell leukemia: No interferon effect on cell growth. *Blood* 66(Suppl 1):228a, 1985.
54. **Foon KA**, Nakano GM, Koller CA, Longo DL and Steis RG: Rapid response to 2'deoxycoformycin (DCF) after failure of recombinant leukocyte \square interferon (rIFN-A) in two patients with hairy cell leukemia (HCL). *Blood* 66(Suppl 1):199a, 1985.
55. **Foon KA**, Carrasquillo JA, Read EJ, Carter CS, Keenan AM, Reynolds HC, Perentesis P and Larson SM: Trafficking of $^{111}\text{Indium}$ (^{111}IN) monoclonal antibody-labeled chronic lymphocytic leukemia (CLL) cells. *Blood* 66(Suppl 1):222a, 1985.
56. Mulshine J, Keenan A, Carrasquillo J, Weinstein J, Reynold J, Larson S, **Foon K** and Bunn P: Successful immunolymphoscintigraphy after lymphatic delivery of ^{111}IN -T101. *Proc Am Soc Clin Oncol* 4:205, 1985.
57. **Foon KA**, Maluish AE, Abrams PG, Wriggington CS, Schnipper EF and Herberman RB: A phase II trial of recombinant leukocyte A interferon (rIFN-A) for advanced hairy cell leukemia. *Proc Am Soc Clin Oncol* 4:221, 1985.
58. Bunn P, Carrasquillo J, Mulshine J, Keenan A, **Foon K**, Schroff R, Reynolds J and Larson S: Successful imaging of cutaneous T-cell lymphoma (CTCL) patients with intravenous ^{111}IN -T101. *Proc Am Soc Clin Oncol* 4:221, 1985.
59. Abrams PG, Carrasquillo J, Schroff R, Morgan AC, Fer M, Keenan A, Larson S and **Foon KA**: Successful imaging of metastatic melanoma with an indium-labeled monoclonal antibody. Tumor localization and biodistribution studies. *Proc Am Soc Clin Oncol* 4:228, 1985.
60. Woodhouse CS, Schroff RW, **Foon KA** and Morgan AC Jr: Factors affecting localization of murine monoclonal antibody 9.2.27 administered to patients with malignant melanoma. *Proc Am Assoc Cancer Res* 26:289, 1985.
61. Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JA, **Foon KA**, Schroff RW, Perentesis P, Stein RG, Keenan AM and Larson SM: Differences in biodistribution of I-131 and In-111 labeled T101 in patients with cutaneous T-cell lymphoma. Society of Nuclear Medicine 33rd Annual Meeting, Washington DC Convention Center, June 22-25, 1986.
62. Munz D, Carrasquillo JA, Newmann RD, Reynolds JC, Abrams P, **Foon KA**, Bunn PA, Mulshine JL, Schroff R, Morgan C and Larson SM: Dose-dependent differences in biodistribution of In-111 labeled monoclonal antibodies (MoAb). Society of Nuclear Medicine 33rd Annual Meeting, Washington DC Convention Center, June 22-25, 1986.

63. Roth MS, Carey JL, **Foon KA**, Harnden CE and Ginsburg D: Discordance of surface phenotype and immunoglobulin genotype: Leu 9 positive acute lymphoblastic leukemia of B-lineage. *Blood* 68(Suppl 1):250a, 1986.
64. Sinkule JA, Buchsbaum DJ, Fodor P, Hanna D, McQuiston S, Stites S, **Foon KA**, Kaminski M, Lichter A and Miller RA: Anticancer drug/radionuclide/monoclonal antibody. Second International Conference on Monoclonal Antibody Immunoconjugates for Cancer, UCSD Cancer Center, San Diego, California, March 12-14, 1987.
65. Huard TK, Heaphy BA, Ruscetti F and **Foon K**: Leukemic hairy cells resist NK cell lysis. *Proc Am Assoc Cancer Res* 28:1499, 1987.
66. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, **Foon KA**, Reynolds JC, Schroff RW, Morgan AC, Larson SM and Weinstein JN: A kinetic model for the biodistribution of an ¹¹¹In-labeled antimelanoma monoclonal antibody in humans. *Proc Am Assoc Cancer Res* 28:1555, 1987.
67. Sinkule JA, Buchsbaum DJ, **Foon K**, Kaminski M and Miller RA: Therapeutic potential of dososcuribin/antibody/radionuclide conjugates in a B-cell lymphoma model. *Proc Am Assoc Cancer Res* 28:1575, 1987.
68. **Foon KA**: Diagnosis and therapeutic applications of monoclonal antibodies in leukemias and lymphomas. 18th International Leukocyte Culture Conference, La Grande-Motte, France, June 19-24, 1987.
69. Carrasquillo JA, Mulshine JM, Reynolds JC, Schroff RW, Bunn PA, Steis RG, Perentesis P, **Foon KA** and Larson SM: Radioimmunoscintigraphy of chronic lymphocytic leukemia (CLL) with monoclonal antibodies. 34th Annual Meeting Society of Nuclear Medicine, Metro Toronto Convention Centre, June 2-5, 1987.
70. Huard TK, Heaphy BA, Sennowitz K, Ruscetti F and **Foon KA**: Susceptibility of leukemic hairy cells to cytolytic effector cells. 29th Annual Meeting, The American Society of Hematology, September 1, 1987.
71. Buchsbaum DJ, Sinkule JA, Stites MS, Fodor PA, Hanna DE and **Foon KA**: Localization and therapy with radiolabeled monoclonal antibodies (MoAb) in nude mice bearing human B-cell lymphoma. 29th Annual Meeting, The American Society of Hematology, September 1, 1987.
72. **Foon KA**: Diagnosis and therapeutic applications of monoclonal antibodies in leukemias and lymphomas. 18th International Leukocyte Culture Conference, La Grande-Motte, France, June 19-24, 1987.
73. Huard TK, Heaphy BA, Ruscetti F and **Foon K**: Leukemic hairy cells resist NK cell lysis. *Proc Am Assoc Cancer Res* 28:1499, 1987.

74. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, **Foon KA**, Reynolds JC, Schroff RW, Morgan AC, Larson SM and Weinstein JN: A kinetic model for the biodistribution of a ¹¹¹In-labeled antimelanoma monoclonal antibody in humans. Proc Am Assoc Cancer Res 28:1555, 1987.
75. Sinkule JA, Buchsbaum DJ, **Foon K**, Kaminski M and Miller RA: Therapeutic potential of doxorubicin/antibody/radionuclide conjugates in a B-cell lymphoma model. Proc Am Assoc Cancer Res 28:1575, 1987.
76. Buchsbaum DJ, Terry VH, Brubaker PG, Stites MS, Hanna DE, Fodor PA and **Foon KA**: Radiolabeled monoclonal antibody (MoAb) localization and therapy *in vitro* and in human cancer in nude mouse models. Radiation Research Society, 36th Annual Meeting; North American Hyperthermia Group, 8th Annual Meeting, 1987.
77. Sinkule JA, Buchsbaum DJ, Fodor P, Hanna D, McQuiston S, Stites S, **Foon K**, Kaminski M, Lichter A and Miller RA: Anticancer drug/radionuclide/monoclonal antibody (MoAb) conjugates: Therapeutic potential in a B-cell lymphoma model. Immunoconjugates, San Diego, 1988.
78. **Foon KA**: Interferon therapy for lymphomas. Interferon in Oncology, Espoo, Finland, June 16-17, 1988.
79. Goldrosen MH, Loftus R, Lloyd F Jr, Biddle W, Paolini N Jr, Holyoke ED and **Foon KA**: Localization of monoclonal antibody in a novel nude mouse model of pancreatic cancer. Proc Am Assoc Cancer Res 29:419, 1988.
80. Buchsbaum D, Sinkule J, Stites M, Fodor P, Hanna D and **Foon K**: Radiolabeled monoclonal antibody localization and therapy in nude mice bearing human B-cell lymphoma. Proc Am Assoc Cancer Res 29:424, 1988.
81. **Foon KA**: Immunologic classification of leukemia and lymphoma: Implications for monoclonal antibody diagnosis and therapy. ACNP/DOE/SNM Joint Symposium on Biology of Radionuclide Therapy, Washington DC, 1988.
82. Han T, Dadey B, Sheedy D, Xiao H, Block AW, O'Donnell A, Bhargava A, Fitzpatrick J, Roth MS, **Foon KA** and Henderson ES: Establishment and characterization of leukemic cell lines from patients with adult B-cell leukemias. Blood 72(Suppl 1):203a, 1988.
83. **Foon KA**: Immunologic classifications of leukemia and lymphoma: Implications for monoclonal antibody diagnosis and therapy. Biology of Radionuclide Therapy Proceedings, September 29, 1988.
84. Chatterjee M, Biddle W, **Foon K** and Köhler H: Anti-idiotype (Id) antibodies against monoclonal antibody to carcinoembryonic antigen (CEA). FASEB J 3:828, 1989.

85. Chatterjee M, **Foon K**, Seon BK, Barcos M and Köhler H: Anti-idiotype monoclonal antibody immunization therapy of cutaneous T-cell lymphoma. Proc Am Assoc Cancer Res 30:382, 1989.
86. Biddle W, Pancook J, Vaickus L, Goldrosen M and **Foon KA**: Immunologic and biologic studies of a Lym-1 ricin conjugate. Proc Am Assoc Cancer Res 30:395, 1989.
87. Goldrosen M, Biddle W, Bakshi S, Paolini N, Pancook J, Morgan AC Jr and **Foon KA**: Radiolocalization of NRU-10 monoclonal antibody in a murine model of experimental hepatic metastases. Proc Am Assoc Cancer Res 30:393, 1989.
88. Biddle W, Loftus R, Paolini N, Pancook J, **Foon K** and Goldrosen M: Construction of a heterobifunctional antibody directed against carcinoembryonic antigen and phthalate. Proc Am Assoc Cancer Res 30:358, 1989.
89. VanderMolen L, Duffey L, Urba W, Longo D, **Foon K**, Smith J II, Clark J, Creekmore S, Hartmann I, Jaffe E, Miller R, Conlon K, Crum F, Stevenson H, Watson T and Steis R: Low-dose (LD) vs high-dose (HD) recombinant interferon alpha-2a (IFN) treatment in favorable histology non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 8:255, 1989.
90. Friedman N, Bernstein Z, Goldrosen M, Krajewski C, Vesper D, Steel J, Arbuck S, Sweeney J, Henderson E, Takita H, Kopec I, Levitt D, Stewart C and **Foon KA**: Phase II trial of IL-2/LAK therapy for patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL) and non-small cell (NSC) lung cancer. Proc Am Soc Clin Oncol 8:194, 1989.
91. Massaro A, Ward MM, Evans SS, Stewart C, **Foon K** and Ward RE: Preferential expression of the gamma, delta TCR in T cells infiltrating B-cell lymphomas. Proc Am Assoc Cancer Res 30:343, 1989.
92. **Foon KA**, Miller RA, Barcos M, Han T, Hart S, Bernstein Z and Chatterjee M: Shared idiotype expression by B-cell leukemia/lymphoma: Unique restricted idioype identified on diffuse lymphomas. Blood 74(Suppl 1):119a, 1989.
93. Jones VE, McNamara-Ward M, Massaro A, **Foon K**, Stewart C and Ward RE: Characterization of gamma-delta T cells by flow cytometry. Blood 244:68a, 1989.
94. Biddle W, Pancook J, Goldrosen MH, **Foon KA** and Vaickus L: IL-2 enhances Lym-1-dependent cellular cytotoxicity of normal and cancer patient mononuclear cells against B lymphoma targets. Blood 835:224a, 1989.
95. Vaickus L, Biddle W, Cemerlic D and **Foon KA**: Gamma-interferon augments Lym-1-dependent, granulocyte-mediated tumor cell cytotoxicity. Blood 543:147a, 1989.

96. Bernstein ZP, Vaickus L, Friedman N, Rahman R, Arbuck S, Henderson E, Goldrosen M, Vesper D, Steel J, Stewart C and **Foon KA**: Interleukin-2 (IL-2) and lymphokine-activated killer cell (LAK) therapy of non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). *Blood* 1056:279a, 1989.
97. Bhattacharya-Chatterjee M, Biddle W, **Foon KA** and Köhler H: Syngeneic monoclonalanti-idiotype related to human carcinoembryonic antigen. *Proc Am Assoc Cancer Res* 31:279, 1990.
98. Arbuck SG, Biddle WC, Keesler C, Stewart C, **Foon K**, Schmeltzer R, Maguire R and Goldrosen MH: Tissue biodistribution and pharmacokinetic analysis of intraperitoneally (IP) administered ⁹⁰Yttrium (⁹⁰Y)-labelled B72.3 reactive adenocarcinomas confined chiefly to the peritoneal cavity. 15th International Cancer Congress, Hamburg, August 16-22, 1990.
99. Biddle WC, Musser DA, Goldrosen MH and **Foon KA**: Selective destruction of malignant human B cells by a photoimmunotherapeutic approach *in vitro*. 15th International Cancer Congress, Hamburg, August 16-22, 1990.
100. Chatterjee M, Biddle W, **Foon KA** and Köhler H: Idiotype vaccines against human gastrointestinal (GI) carcinoma. 15th International Cancer Congress, Hamburg, August 16-22, 1990.
101. Arbuck SG, Biddle WC, Keesler C, Stewart C, **Foon KA**, Schmelter R, Maguire R and Goldrosen MH: Pharmacokinetic analysis of intraperitoneally administered ⁹⁰Yttrium-labelled B72.3 reactive adenocarcinomas. *Proc Am Assoc Cancer Res* 31:174, 1990.
102. Biddle WC, Musser DA, Goldrosen MH and **Foon KA**: Selective destruction of malignant human B cells by a photoimmunotherapeutic approach *in vitro*. *Proc Am Assoc Cancer Res* 31:293, 1990.
103. Cemerlic DZ, Genco J, Zgoda L, Neubauer J, **Foon KA**, Dadey B, Han T and Vaickus L: Cytokine augmentation of Lym-1-dependent, granulocyte-mediated lysis (ADCC) of chronic lymphocytic leukemia (CLL) tumor cells. *Proc Am Assoc Cancer Res* 31:287, 1990.
104. Watanabe H, Stewart CC, Arbuck SG, **Foon KA** and Goldrosen MH: The effect of anti-CD3 on lymphokine activity killer cell induction. *Proc Am Assoc Cancer Res* 31:278, 1990.
105. Biddle WC, Goldrosen MH, Schroff R, Morgan AC, Gregor KR, Pancook JD and **Foon KA**: Characterization of an anti-variant HLA-DR monoclonal antibody. *Proc Am Assoc Cancer Res* 31:284, 1990.

106. Biddle WC, Bakshi, Krajewski C, Loftus R, Pancock J, Peacock J, **Foon KA** and Goldrosen MH: Radiolocalization of an anti-CEA monoclonal antibody with restricted specificity. Proc Am Assoc Cancer Res 31:264, 1990.
107. Bielat KL, Biddle W, Vaickus L, Goldrosen MH and **Foon KA**: Ultrastructural observations of the interaction of Lym-1 monoclonal antibody with Raji Burkitt lymphoma cells. Proc Am Assoc Cancer Res 31:269, 1990.
108. Henderson ES, **Foon K**, Stewart C, Kelly S and Dadey B: The use of CD5 DIM/CD5 bright expression in B-CLL as a clinical monitoring tool of therapy effectiveness. Blood 78(Suppl 1):465a, 1991.
109. Bernstein ZP, Walther PJ, Vaickus L, Goldrosen M, Vesper D, Huben R, Lynch W Jr and **Foon KA**: Treatment of renal cell carcinoma with Interleukin-2 (IL-2) and phenylalanine methyl ester (PME) pretreated lymphokine activated killer cells (LAK). Proc Am Soc Clin Oncol 10:181, 1991.
110. Bernstein ZP, Vaickus L, Goldrosen M, Vesper D, Takita H, Zeffren J and **Foon KA**: Interleukin-2 (IL-2) and lymphokine activated killer cell (LAK) therapy of non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 10:285, 1991.
111. Villalona-Calero M, Stewart C, Barcos M, Baiocchi M, Caligiuri M and **Foon KA**: Phenotypic characteristics of "prolymphocytoid" transformed (CLL/PLL) chronic lymphocytic leukemia (CLL) cells. Proc Am Soc Clin Oncol 10:230, 1991.
112. Goldrosen MH, Stewart C, Biddle W, Bakshi W, **Foon KA**, Abdel-Nabi H, Spaulding M, Doerr R, Schmelter R, Maguire R and Arbuck SG: Biodistribution and pharmacokinetic (PK) analysis of intraperitoneally (IP) administered ⁹⁰Y-labeled B72.3 (⁹⁰Y-CYT-103) in patients with TAG-72 reactive tumors. Proc Am Assoc Cancer Res 32:271, 1991.
113. Abdel-Nabi H, Spaulding M, Goldrosen M, Bakshi S, **Foon KA**, Evans N, Farrell E, Kiessler C, Gona J, Doerr R, Schmelter R, Maguire RT and Arbuck S: Phase I clinical trial of intraperitoneally injected ⁹⁰Y-labeled B72.3 (CYT-103) MoAb for refractory colorectal adenocarcinomas confined to the abdominal cavity. Sixth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. February 28-March 1, 1991.
114. Watanabe H, **Foon K** and Goldrosen MH: Growth regulatory effects of medium obtained from peripheral blood mononuclear cell (PBMC) primed with anti-CD3 and r-Interleukin-2 (rIL-2). Proc Am Assoc Cancer Res 32:83, 1991.
115. Goldrosen MH, Loftus RJ and **Foon KA**: Binding and penetration of ¹²⁵I-D14, an anti-carcinoembryonic antigen (CEA) monoclonal antibody (MoAb) in a novel tumor histoculture system. Proc Am Assoc Cancer Res 32:275, 1991.

116. Mukerjee S, **Foon KA**, Ceriani R, Köhler H and Bhattacharya-Chatterjee M: Syngeneic monoclonal anti-idiotype antibodies against a monoclonal antibody to human breast cancer-associated antigen. *FASEB J* 5:A1713, 1991.
117. Bhattacharya-Chatterjee M, **Foon KA**, Zhang J, Petrelli N and Köhler H: Idiotype matching: Level of expression of a network antigen idiotype in colon cancer patients' sera. *FASEB J* 5:A1356, 1991.
118. **Foon KA**, Rai KR and Gale RP: Chronic lymphocytic leukemia: New insights into biology and therapy. *Oncol Dig* 2:18-20, 1991.
119. **Foon KA**, Vaickus L, Osseroff A, Stoll H, Köhler H and Chatterjee M: Phase 1 trial of anti-idiotype monoclonal antibody vaccine therapy for patients with cutaneous T-cell lymphoma. *Proc Am Soc Clin Soc* 11:337, 1992.
120. Mukerjee S, **Foon KA**, Ceriani R, Köhler H and Bhattacharya-Chatterjee M. Generation of anti-anti-idiotype antibodies (Ab3) that recognize human breast cancer-associated antigen. *FASEB J.* 6:A2059, 1992.
121. Chakraborty M, Sherratt AJ, **Foon KA**, Ceriani R, Köhler H and Bhattacharya-Chatterjee M. Induction of human breast cancer-specific antibody response in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody. *Proc Am Assoc Cancer Res.*, 35:497, 1994.
122. Fleming DR, Henslee-Downey PJ, Harder EJ, Romond EH, Messino M, Macdonald JS, Rayens MK, Marciak E, Bishop MR, Ciocci G, Thompson JS and **Foon KA**. Partially matched related donor allogeneic bone marrow transplantation (BMT) in recurrent acute lymphoblastic leukemia (ALL). *Blood* 84(suppl 1):10, 1994.
123. **Foon KA**, Bhattacharya-Chatterjee M, Chakraborty M, John WJ, Köhler H and Sherratt AJ. Murine anti-idiotype (Id) monoclonal antibody (mAb) induces specific humoral responses to carcinoembryonic antigen (CEA) in colorectal cancer (CRC) patients. *Proc Am Soc Clin Oncol*. Dallas, TX, May 1994.
124. Maloney DG, Bodkin D, Grillo-Lopez AJ, White C, **Foon KA**, Schilder R, Neidhart J, Janakiraman N, Waldichuk C, Varns C, Royston I and Levy R. IDEC-C2B8: Final report on a phase II trial in relapsed non-hodgkin's lymphoma. *Blood* 84(suppl 1):10, 1994.
125. White CA, Grillo-Lopez AJ, Maloney D, Bodkin D, Schilder R, **Foon KA**, Neidhart J, Janakiraman N, Dallaire B, Shen D, Royston I, and Levy R. PIDEC-C2B8: Improved tolerance correlated with pharmacodynamic effects in patients with B-cell NHL. *Proc Am Assoc Cancer Res* (in press)
126. Chatterjee SK, Tripathi PK, Qin H-X, Xu C, **Foon KA** and Bhattacharya-Chatterjee M. Construction of vectors for expression of functional anti-idiotype antibody fragments.

ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA, June 2-6, 1996. FASEB J. 10(6):A1059, 1996.

127. Sen G, Chakraborty M, **Foon KA**, Reisfeld and Bhattacharya-Chatterjee M. An alternative strategy for inducing predominately IgG antibodies and T cell responses against disialoganglioside GD2 using an anti-idiotype antibody. ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA, June 2-6, 1996. FASEB J. 10(6):A1059, 1996.
128. Chakraborty M, **Foon KA** and Bhattacharya-Chatterjee M. Serological response patterns of colorectal cancer (CRC) patients immunized with an anti-idiotype antibody. ASBMB/ASIP/AAI Joint Meeting, New Orleans, LA, June 2-6, 1996. FASEB J. 10(6):A1346, 1996.
129. Qin H-X, Tripathi PK, Xu C, Bhattacharya-Chatterjee M, **Foon KA** and Chatterjee SK. Significance of the variable domain order and linker for the activity of anti-idiotype antibody fragments expressed in bacteria. Allerg Clin Immunol. 99:No 1, Part Z, 5214, 1997.
130. **Foon KA**, Sen G, Chakraborty M, Reisfeld R, Garrison J and Bhattacharya-Chatterjee M. Anti-Idiotype (Id) monoclonal antibody (mAb) that induces a specific humoral response to the GD2 ganglioside in advanced melanoma patients. Amer Soc Clin Oncol. Annual Meeting, 1997,
131. Munn RK, Hutchins L, Garrison J, Sen G, Chakraborty M, Baral R, Romond E, Bhattacharya-Chatterjee M and **Foon KA**. Immune responses in patients with breast cancer treated with an anti-idiotype antibody that mimics the human milk fat globulin (HMFG) antigen. ASCO, May 16-19, 1998, Los Angeles, CA. Proc ASCO 17:428a, 1998.
132. Bhattacharya-Chatterjee M, Sen G, Baral R, Banerjee M, Garrison J, Reisfeld RA and **Foon KA**. Immune responses in advanced melanoma patients immunized with an anti-idiotype (ID) antibody mimicking disialoganglioside GD2. ASCO, May 16-19, 1998, Los Angeles, CA. Proc ASCO 17:435a, 1998.
133. **Foon KA**, John WJ, Chakraborty M, Garrison J, Bard V and Bhattacharya-Chatterjee M. Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with an anti-idiotype (ID) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5-fluorouracil (5-FU). ASCO, May 16-19, 1998, Los Angeles, CA. Proc ASCO 17:435a, 1998.
134. Reece D, **Foon K**, Chatterjee M, Howard D, Munn R, Teitelbaum A, and Phillips G. Use of the anti-idiotype (ID) antibody (AB) vaccine 11D10 (TRIAB) after intensive therapy (IT) and autologous blood stem cell transplantation (ASCT) in patients (PTS) with metastatic breast cancer (MBC). Gene Therapy of Hematopoietic Diseases; 94(Suppl 1):397a, 1999.
135. Manna S, Tripathi PK, Qin H-X, Bhattacharya-Chatterjee M, **Foon KA** and Chatterjee

- SK. DNA vaccines based on the structure of an anti-idiotype antibody (3H1) mimicking carcinoembryonic antigen (CEA). *Proc. Amer. Assoc. Cancer Res.* 40:323, 1999.
136. **Foon KA**, Lutzky J, Yanelli J, Hutchins L, Kashala O, Garrison J, Reisfeld RA, Teitelbaum A, Chatterjee M. Clinical and immune responses in melanoma patients immunized with an anti-idiotype (ID) antibody mimicking GD2. *Proc. Amer. Soc. Clin. Oncol.* (ASCO Mtg.) May 15 – 18, 1999.
137. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, **Foon KA** and Chatterjee SK. Long lasting in vivo expression of transgene after immunization with a plasmid expressing the single chain variable fragment (scFv) of the anti-idiotype antibody mimicking GD2 ganglioside. Abst. presented at Keystone Symposia on Molecular and Cellular Biology, April 13, 1999.
138. Reece D, **Foon KA**, Bhattacharya-Chatterjee M, Connaghan G, Holland K, Munn R, DiPersio J, Simpson D, Teitelbaum A and Phillips GL. Anti-idiotype vaccination plus intensive therapy and autologous stem cell transplantation for patients with metastatic breast cancer. *Europ. J. Cancer* 35(Suppl 4):5353, 1999.
139. **Foon KA**, Lutzky J, Yanelli J, Hutchins L, Kashala O, Garrison J, Reisfeld RA, Teitelbaum A, Chatterjee M. Clinical and immune responses in melanoma patients immunized with an anti-idiotype (ID) antibody mimicking GD2. *PROLEUKIN Second International Congress*, July 29 – August 1, 1999.
140. **Foon KA**, John WJ, Chakraborty M, Das R, Teitelbaum A, Chatterjee SK, Bhattacharya-Chatterjee M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. *J Clin Oncol.* 17:2889-2895, 1999.
141. Manna S, Chakraborty M, Bhattacharya-Chatterjee M, Tripathi PK, Qin H-X, **Foon KA**, Zeytin H and Chatterjee SK. Mimicry of an epitope on carcinoembryonic antigen (CEA) by a peptide derived from the anti-idiotype antibody, 3H1. *Proc. Am. Assoc. Cancer Res.* 41:877, 2000.
142. Reece D, **Foon KA**, Chatterjee M, Connaghan DG, Holland HK, Howard D, Munn RK, Nath R, Raptis H, Klingemann, Teitelbaum A and Phillips GL. Vaccination with TriAb in conjunction with intensive therapy and autologous stem cell transplantation for patients with metastatic breast cancer. *Proc. of ASCO.* 19;388, 2000.
143. Qin H-X, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, **Foon KA**, O'Malley BW and Chatterjee SK. Therapy of head and neck cancer by recombinant vaccinia virus expressing IL-2 in amurine model and evidence of immune suppression. *Proc Am Assoc Cancer Res* 42:818, 2001.
144. Safa M, Lutzky J, Chatterjee M, Sussman J, Bard V, Baral R, Das R, Saha A, Shukla R,

- Reisfeld R, Hutchins L, Bhatnagar A, **Foon KA**. TriGem anti-idiotype (Anti-Id) Monoclonal antibody (MAb) treatment for stage III melanoma: results of a multicenter phase II trial. *Proc. of ASCO Mtg.* 5/13/01.
145. Chatterjee M, Lutzky J, Safa M, Sussman J, Bard V, Baral R, Das R, Saha R, Shukla R, Reisfeld R, Hutchins L, Bhatnagar A, **Foon KA**. Immune and clinical comparison of different adjuvants combined with TriGem: an anti-idiotype (Anti-Id) monoclonal antibody (MAb) treatment for stage III melanoma. *Proc. of ASCO*. 5/01.
146. Bhatnagar A, Lowy A, Rohatgi N, Chatterjee M, Bard V, Baral R, Saha A, **Foon KA**, Das R. CeaVac anti-idiotype (Anti-Id) monoclonal antibody (Mab) therapy of colon cancer patients: comparison of different routes of administration using an alugel preparation of vaccine. *Proc of ASCO*. 5/01.
147. Rohatgi N, Bhatnagar A, Lowy A, Chatterjee M, Bard V, Baral R, Saha A, Das R, Shukla R, John W, **Foon KA**. CeaVac anti-idiotype (Anti-Id) monoclonal antibody (Mab) treatment for resected colorectal cancer (CRC): results of a phase II trial. *Proc. of ASCO*. 5/01.
148. R. Figlin, A. Belldgegrun, J. Crawford, M. Lohner, L. Roskos, X-D. Yang, **K.A. Foon**, F. Schwab, L. Weiner: ABX-EGF, A fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody (Mab) in patients with advanced cancer: phase 1 clinical results. ASCO Proceedings 5/02.
149. G. Schwartz, J. Dutcher, N. Vogelzang, J. Gollob, J. Thompson, R. Bukowski, R. Figlin, M. Lohner, L Roskos, C.C. Hwang, **K.A. Foon**, G. Schwab, E. Rowinsky: Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). ASCO proceedings 5/02.
150. A. Saha, S.K. Chatterjee, S. Pal, **K.A. Foon**, M. Bhattacharya-Chatterjee: Bone marrow derived dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) elicit protective anti-tumor immunity in CEA-transduced syngeneic murine carcinoma model. *Proc. Am. Assoc. Cancer Res.* 43: 281, 2002.
151. R.N. Baral, S.K. Chatterjee, A. Saha, R. Das, **K.A. Foon**, A.M. Krieg, G.J. Weiner, M.B. Chatterjee: Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. *Proc. Am. Assoc. Cancer Res.* 43: 976, 2002.
152. L. Weiner, R. Figlin, A. Belldgegrun, G. Schwartz, J. Dutcher, N. Vogelzang, J. Gollob, J. Thompson, R. Bukowski, J. Crawford, **K.A. Foon**: ABX-EGF A Fully Human Anti-epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (MAb): Results of a Phase 1 Study and a Phase 2 Renal Cell Cancer (RCC) Study. *J Immunother.*, Vol. 25, S28, No. 6, 2002

153. C. Palena, L. McIntosh, J. Schlom, **K.A. Foon**, and K.Y. Tsang. Modification of B-CLL Cells via Infection with a Replication-Defective MVA virus encoding Three Costimulatory Molecules: A Potential Approach to Tumor Call Immunotherapy of B-CLL. American Society of Hematology 46th Annual Meeting Program and Abstracts, Blood 104:11, Pt 1 of 2 Pts; 2004.
154. S.A. Jacobs, A. M. Harrison, S.H. Swerdlow, **K.A. Foon**, N. Avril, V. Vidnovic, K.S. McCarty, and W. Seville. Cellular localization pattern of Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin®) in a patient with Low-grade non-Hogkin's lymphoma (NHL). American Society of Hematology 46th Annual Meeting program and Abstracts, Blood 104:11; Pt 2 of 2 Pts, 2004.
155. M.A. Melan, **K.A. Foon**, S.M. Marks, and J.A. Kant. Immunoglobulin Havey Chain (IgH) Gene Somatic Hypermutation Status Using Homoduplex-Separated RT-PCR Products. American Society of Hematology 46th Annual Meeting program and Abstracts, Blood 104:11; Pt 2 of 2 Pts, 2004.
156. **K.A. Foon**, S. Allen, S. Kaushik, A. Mohrbacher, S. Shamel, L. Lenaz, R. Rosales. Results of a Multi-Center, Phase II Study of Elsamitruclin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL). American Society of Hematology 47th Annual Meeting program and Abstracts, Blood 106:11; Pt 2 of 2 Pts, 2005
157. N.A. DeMonaco, M. Wu, J. Osborn, T. Evans, **K.A. Foon**, S.H. Swerdlow, J.A. Kant, J. Joyce, S. Land, and S.A. Jacobs. Phase II trial of abbreviated CHOP-Rituximab followed by ⁹⁰Y Ibritumomab Tiuxetan (Zebalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL). American Society of Hematology 47th Annual Meeting program and Abstracts, Blood 106:11; Pt 1 of 2 Pts, 2005.
158. A.G. Brickner, J.K. Mito, X. Feng, T. Nishida, L. Fairfull, R.E. Ferrell, **K.A. Foon**, S.R. Riddell, and E.H. Warren. An alternative transcript of the PANE1 gene encodes a minor histocompatibility antigen that is selectively expressed in resting CD19+ cells and B-CLL. American Society of Hematology 47th Annual Meeting program and Abstracts, Blood 106:11; Pt 1 of 2 Pts, 2005.
159. S.A. Jacobs, S.A. Swerdlow, N. Avril, N. Vidnovic, **K.A. Foon**, A.M. Harrison, and K.S. McCarty. Localization of yttrium 90 ibritumomab tiuxetan (⁹⁰Y IT) in patients with CD20+ non-Hodgkin's Lymphoma (NHL). 2005 ASCO Annual Meeting Proceedings; J Clin Onc, Vol. 23, No. 16S Part I of II, 2005.
160. A. A. Tarhini, S. Land, F. Lim, G. J. Kiefer, L. Pietragallo, R. A. Pinkerton, M. Sulecki, D. Meisner, P. M Schaefer, **K.A. Foon**. Early results of modified fludarabine, cyclophosphamide, and rituximab (mFCR) for patients with previously untreated advanced chronic lymphocytic leukemia (CLL). 2006 ASCO Annual Meeting Proceedings; J Clin Onc, Vol. 24, No. 18S Part I of II, 2006.

161. A.A. Tarhini, S. Land, D. Meisner, L. Pietragallo, M. Sulecki, F. Lim, G.J. Kiefer, R. Pinkerton, J. Osborn, S. Sukaly, P.M. Schaefer, **K.A. Foon**. Early Clinical and Pharmacokinetic Results of Lower Dose Fludarabine and Cyclophosphamide, and High Dose Rituximab (FCR-Lite) for Patients with Untreated Chronic Lymphocytic Leukemia (CLL). 2006 ASH Annual Meeting Proceedings; Blood 106: abstract 2844, 2006.

4. Other Publications

1. **Foon KA** and Gale RP: Post-transfusion hepatitis in acute myelogenous leukemia. *JAMA* 246:216, 1981 (letter)
2. **Foon KA**, Zighelboim J and Gale RP: Treatment of acute myelogenous leukemia in older patients. *N Engl J Med* 305:1470, 1981. (letter)
3. **Foon KA**: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. *N Engl J Med* 307:686, 1982. (letter)
4. Bernhard MI, **Foon KA**, Oldham RK and Keenan A: The importance of traditional methods of measuring tracer biodistributions. *Cancer Res* 44:2731-2732, 1984. (letter)
5. **Foon KA** and Dougher G: Increased growth of eyelashes in a patient given leukocyte A interferon. *N Engl J Med* 311:1259, 1984. (letter)
6. **Foon KA** and Schroff RW: The uses of monoclonal antibodies in the diagnosis and treatment of leukemia and lymphoma. *In: In Vitro Monography*, No. 5. 1984, pp 169-188.
7. Abrams PG, McClamrock EA and **Foon KA**: Evening administration of alpha interferon. *N Engl J Med* 312:443-444, 1985. (letter)
8. Reynolds CW, **Foon KA** and Herberman RB: Terminology in T_{lym} lymphoprolifertive disease. *Blood* 66:248-249, 1985. (letter)
9. **Foon KA**: Interferon-alpha: The next decade. *Interactions* 1:3, 1986. (editorial)
10. **Foon KA**: Interferons. Hoffman La Roche, 1986. (video)
11. **Foon KA**: Biological therapy of chronic myelogenous leukemia. *Oncology* 1:49-52 1987. (editorial)
12. **Foon KA**: Application of monoclonal antibodies in the diagnosis and therapy of cancer. NeoRx Pharm Inc, 1988, pp 1-27. (monograph)
13. **Foon KA**: Antibody Structure and Function. NeoRx Pharm Inc, 1988. (video).

14. **Foon KA:** Therapy of Acute Leukemia: Recent Progress and Future Directions. Wyeth Laboratories, 1988. (video)
15. **Foon KA**, Champlin RE and Gale RE: Therapy of acute lymphoblastic leukemia. UCLA Symposium. In: *Acute Lymphoblastic Leukemia*, Vol. 108., pp 157-196, 1990.
16. Vaickus L and **Foon KA**: Clinical immunology at Roswell Park Cancer Institute. Biotherapy of cancer. Oncoline, pp 3-4, 1990. (editorial)
17. Foon KA, Gale RP: Is there a T-cell form of chronic lymphocytic leukemia. Leukemia 6:867-8, 1992. Leukemia 7:916-8, 1993. (letter)
18. **Foon KA:** Cancer Vaccine Therapy: New Approaches, Video Journal of Oncology, Secaucus, NJ 1993. (video)
19. **Foon KA** and Bhattacharya-Chatterjee M. Idiotype vaccines in the clinic. Nature Med 4:870, 1998. (letter)

TEACHING

Biotherapy: New Opportunities for Cancer Treatment, Grand Rounds, Scripps Clinic and Research Foundation, La Jolla, CA, February 28, 1992.

Acute Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, August 16, 1993.

Hodgkin's Disease, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 10, 1993.

Biologic Therapy and Growth Factors, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, October 8, 1993.

Anti-Idiotype Immunotherapy in Cancer Patients, Lecture-Division of Clinical Chemistry, University of Kentucky Hospital, Lexington, KY, April 27, 1994.

Chronic Lymphocytic Leukemia, Internal Medicine Grand Rounds, University of Kentucky Medical Center, Lexington, KY, July 6, 1994.

Acute Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, August 16, 1994.

Anti-Idiotype Vaccine Therapy of CEA positive tumors, Internal Medicine Research Seminar, University of Kentucky Medical Center, Lexington, KY, September 8, 1994.

Melanoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, February 3, 1995.

Lymphoma, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, March 23, 1995.

Chronic Lymphocytic Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, April 28, 1995.

Overview of the Cancer Center, Health Administration, University of Kentucky Medical Center, June 22, 1995.

Non-Hodgkin's Lymphoma, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, September 11, 1995.

Hodgkin's Disease, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 15, 1995.

Non-Hodgkin's Lymphoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 29, 1995.

Chronic Lymphoid Leukemias, Hematology-oncology grand Rounds, Confernce, Univeristy of Cincinnati, Cincinnati, OH, September 28, 2000

Colon Cancer, Internal Medicine residency Program, University of Cincinnati, Cincinnati, OH, September 27, 2000

Non-Hodgkin's Lymphoma, Internal Medicine residency Program, University of Cincinnati, Cincinnati, OH, June 26, 2000

Melanoma, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, April 14, 2000.

Lymphoma, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, March 13, 2000.

Anti-Idiotype Cancer Vaccines, Children's Hospital Medical Center Research Foundation, Basic Sciences, Cincinnati, OH, January 31, 2000.

Cancer Research, Division of Pharmacology, Ph.D. Program, University of Cincinnati, OH, January 7, 2000.

Lymphomas, Internal Medicine Residency Program, University of Cincinnati, Cincinnati, OH, January 6, 2000.

Melanoma, Internal Medicine Residents, University of Cincinnati Hospital, June 24, 1999.

Anti-Idiotype Cancer Vaccines, Children's Hospital Medical Center Research Foundation, Basic Scientists, January 31, 2000.

Cancer Research, Division of Pharmacology, Ph.D. Program, University of Cincinnati College of Medicine, January, 7, 2000.

Lymphomas, Internal Medicine Residents, University of Cincinnati Hospital, January 6, 2000

Melanoma, Internal Medicine Residents, University of Cincinnati Hospital, Cincinnati, OH, December 9, 1999.

Lymphomas, Internal Medicine Residents, University of Cincinnati Hospital, October 4, 1999.

Lymphomas, Internal Medicine Residents, University of Cincinnati Hospital, September 14, 1999.

A Novel Immunotherapeutic Approach for the Adjuvant Treatment of Colon Cancer, Internal Medicine Grand Rounds, University of Kentucky Medical Center, Lexington, KY, September 4, 1996.

Melanoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, August 16, 1996.

Acute Leukemia, Internal Medicine Residency Program, University of Kentucky Medical Center, Lexington, KY, August 8, 1996.

Low Grade Lymphomas, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, June 28, 1996.

Problem Based Learning Tutor Session, Internal Medicine, University of Kentucky Medical Center, April 1-15, 1996.

Leukemia and Lymphoma, Physician Assistants Lecture, University of Kentucky Medical Center, March 7, 1996.

Acute Leukemias, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, February 2, 1996.

Non-Hodgkin's Lymphoma, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 29, 1995.

Hodgkin's Disease, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, September 15, 1995.

Low Grade Lymphomas, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, June 28, 1996.

Problem Based Learning Tutor Session, Internal Medicine, University of Kentucky Medical Center, April 1-15, 1996.

Leukemia and Lymphoma, Physician Assistants Lecture, University of Kentucky Medical Center, March 7, 1996.

Acute Leukemias, Hematology/Oncology Fellows Board Review Lecture Series, University of Kentucky Medical Center, February 2, 1996.

Grand Rounds, University of Cincinnati Hospital, Cincinnati, OH, 2004.

Medical Grand Rounds, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, 2004

Presentations for Lymphoma/Leukemia Tumor Board, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, 2003-2006.

Presentations for Hematologic Malignancies Program Seminar Series, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, 2003-2006.

Presentations for Biologic Therapeutics Committee, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, 2003-2006.

Presentations for Hematologic Malignancy Steering Committee, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, 2003-2006.

Nipent® (pentostatin) in CLL, Supergen Nipent® Strategic Planning Community Advisory Board, Detroit, Michigan, August 6, 2005.

Recent Advances in the Biology and Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Supergen, January 14, 2005

Leukemia and Lymphoma, Houseteaching Staff Lecture Series for Residents, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, July 17, 2003; October 24, 2003; and November 7, 2003.

Leukemia and Lymphoma, Houseteaching Staff Lecture Series for Residents, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, February 24, 2004; April 1, 2004; May 10, 2004, and June 22, 2004.

Leukemia and Lymphoma, Houseteaching Staff Lecture Series for Residents, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology, January 14, 2005; February 15, 2005; March 29, 2005; May 23, 2005; July 21, 2005.

Monoclonal Antibodies and The Paradigm Shift in the Treatment of B-Cell Lymphomas and Leukemias, Hematology/Oncology Fellows Lecture Series, University of Pittsburgh School of Medicine/Department of Hematology/Oncology, June 17, 2005.

Recent Advances in the Biology and Treatment of Low Grade Lymphomas, Lecture Series for Hematology/Oncology Fellows, University of Pittsburgh School of Medicine, Department of Medicine, Division of Hematology/Oncology; May 5, 2006.

Leukemia and Lymphoma, Houseteaching Staff Lecture Series for Residents, University of Pittsburgh School of Medicine/Department of Hematology/Oncology, March 2, 2006; May 1, 2006; June 8, 2006; July 18, 2006.

Recent Advances in the Biology and Treatment of Low Grade Lymphomas “Overview of Lymphoma” as part of Neoplasia Course; Facilitator for Case 4 “Erythocytosis” of PBL cases; January 2005.

“Recent Advances and Clinical Aspects in the Treatment of CLL,” sponsored by Georgia Cancer Foundation, Atlanta, GA, March 23, 2006

Current Therapeutic Modalities in the Management of CLL, Cleveland, OH, April 20, 2006.

Mentored Jennifer Larson, 4th year Medical student, and assisted w/her poster presentation, summer 2005.

Mentored Christopher Marsh, MD, resident, and assisted him w/his presentation, spring 2006.

“Recent Advances and Clinical Aspects in the Treatment of CLL/SLL,” Hematology/Oncology Fellows CME Lecture, University of Pittsburgh School of Medicine/Department of Hematology/Oncology, Sponsored by Berlex Pharmaceuticals, Soba Restaurant, Shadyside, Pittsburgh, PA, September 12, 2006.

“Recent Advances and Clinical Aspects in the Treatment of CLL/SLL,” Oncology Grand Rounds, USC Keck School of Medicine, Los Angeles, California, sponsored by CBCE Speakers Corp., September 22, 2006.

“Clinical Care of Lymphoproliferative Disorders,” Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, part of Hematology Course for 4th year Medical School Students, January 11, 2007.

RESEARCH:

1. Current Grant Support:

| Grant Number <u>(Funded)</u> | Grant Title | Role in Project & Effort (in cal. Mths.) | Years <u>Inclusive</u> | Source <u>\$ Amount</u> |
|---|---|---|-----------------------------------|------------------------------------|
| NIH RO1 CA72018 | Ganglioside GD2 as Target for Immunotherapy in Melanoma | PI 3.0 | 8/01/05- 8/30/09 | \$1,250,000 (direct) |

| | | | | | |
|-----------|---|----|-----|------------------|-----------------------|
| C-Change | A Statewide Cancer Clinical Trials Network in Pennsylvania | PI | 1.8 | 7/1/05-12/31/07 | \$200,000 (direct) |
| Genentech | Fludarabine, cyclo-phosphamide and rituximab for untreated patients with chronic lymphocytic leukemia | PI | 9.0 | 9/1/04 – 9/30/06 | \$103,750 (direct) |

2. Prior Grant Support

Louis Sklarow Memorial Fund, "Monoclonal Antibodies for B-Cell Lymphomas," Kenneth A. Foon, M.D., Principal Investigator, 7/1/86 - 6/31/87, \$42,000 (total cost).

NIH 1 RO1 CA43212-01, "Mechanisms of Interferon Action in Hairy-Cell Leukemia," Kenneth A. Foon, M.D., Principal Investigator, 9/30/86 - 6/30/89, \$173,960 (total direct cost).

NIH PO1 CA42768, "Radiopharmaceutical Diagnosis and Treatment of Cancer," Subproject: "Preclinical and Clinical Treatment with Monoclonal Antibodies to B-Cell Lymphomas," Kenneth A. Foon, M.D., Principal Investigator, 9/30/87 - 2/28/89, \$265,803 (total direct cost).

"A Phase I/II Study of High-Dose, Continuous-Infusion Recombinant Human Interleukin-2 with Non-Small Cell Lung Cancer and Resistant Lymphoma," Kenneth A. Foon, M.D., Principal Investigator, Hoffmann La Roche, Inc., 10/1/88 - 9/30/89, \$50,000 (total cost).

"A Phase I/II Clinical Investigation to Evaluate the Safety and Efficacy of Continuous Infusions of Recombinant Interleukin-2 and Phenylalanine Methyl Ester Pretreated Cells in Patients with Unresectable and/or Metastatic Melanoma and Renal Cell Cancer," Kenneth A. Foon, M.D., Principal Investigator, Dupont Corporation, 1/1/89 - 12/31/90, \$270,000 (total cost).

NIH RO1 CA47860, "Idiotype Approach to Therapy of Human T-Cell Leukemia," Malaya Chatterjee, Ph.D., Principal Investigator, Kenneth A. Foon, M.D., Co-Investigator (10%), 4/1/89 - 3/31/92, \$381,495 (total direct cost).

"Therapy of Renal Cell Carcinoma and Malignant Melanoma with Interleukin-2," Kenneth A. Foon, M.D., Principal Investigator (5%), Hoffmann La Roche, Inc., 6/1/90 - 5/31/91, \$39,000 (total cost).

NIH 1PO1 CA4767-03 (Consortium), "Monoclonal Antibody Therapy of Breast Cancer," R. Ceriani, M.D., Program Director; ^{111}In -Labeled Monoclonal Antibody Imaging of

Metastatic Breast Cancer," Kenneth A. Foon, M.D., Principal Investigator (5%), 1/2/91 - 8/31/91, \$96,025 (total direct cost).

Buffalo Foundation Grant 857-0484A, "Feasibility Study of Anti-Idiotype Monoclonal Antibody Therapy for Patients with Cutaneous T-Cell Lymphoma," Kenneth A. Foon, M.D., Principal Investigator (5%), 3/1/91 - 2/29/92, \$7,000 (total cost).

NIH 1PO1 CA58880-01A2 (Program Project Grant), "Monoclonal Antibody Therapy for GI Cancer," Kenneth A. Foon, M.D., Principal Investigator (20%), 9/1/91 - 8/31/94, \$900,000 (total direct cost).

NIH RO1 CA54321-01 (Consortium), "Structure-Function of Tumor-Anti-Idiotype Antibodies," Heinz Köhler, M.D., Ph.D., Principal Investigator; "Generation of Tumor-Anti-Idiotypic Antibodies," Malaya Chatterjee, Ph.D., Principal Investigator, Kenneth A. Foon, M.D., Co-Investigator (10%), 7/1/91 - 6/30/94, \$130,902 (total direct cost).

Share Foundation, "Phase Ib Study of Monoclonal Anti-Idiotype Antibody Therapy for Patients with Metastatic Melanoma," 1/1/93 - 12/31/95, \$125,000 (total cost).

Ortho Pharmaceutical Corp. - Treatment of previously untreated chronic lymphocytic leukemia, 1994-95, \$50,000.

Tobacco & Health, Anti-Idiotype Vaccine for Human Small Cell Lung Carcinoma, 7/1/94-6/30/95, \$79,900 (total direct cost).

NCI 1PO1 CA57165-04 (Program Project Grant), "Monoclonal Antibody Therapy of GI Cancer", Kenneth A. Foon, M.D., Principal Investigator. Project 1. "Generation of Anti-Idiotype Tumor Vaccines", M. Chatterjee, Ph.D., Principal Investigator. 9/30/91 - 8/31/95, \$768,027 (direct cost), \$126,221 (indirect cost).

Berlex, Treatment of previously untreated low grade follicular lymphoma, Kenneth A. Foon, M.D., Principal Investigator, 1994-95, \$51,000.

NCI 5U10 CA46136-07, Southwest Oncology Group Clinical Study, Kenneth A. Foon, M.D., Principal Investigator, 1/1/88 - 12/31/97, \$507,164 (direct cost), \$244,266 (indirect cost).

NIH R01 CA60000-02, Anti-Idiotype Vaccine for Breast Cancer, Kenneth A. Foon, M.D., Principal Investigator, 12/1/94 - 11/30/97, \$477,406 (total direct cost), \$233,929 (indirect cost).

P20-, Planning Grants for Prospective Cancer Centers, Kenneth A. Foon, M.D., Principal Investigator, 8/1/95 - 7/30/97, \$350,000 (direct cost), \$171,500 (indirect cost).

NIH NCI R01 CA72773-03, "Immunotherapy of Cancer with Anti-Id Based DNA Vaccines", Principal Investigator, Sunil K. Chatterjee, Ph.D., 10/01/99- 12/31/99.

Lucille P. Markey Charitable Trust, Research Program Grant, Kenneth A. Foon, M.D., Principal Investigator, 1/2/95 - 2/15/99, \$1,900,000 (total direct cost).

NIH R03 CA79401-01, Anti-Idiotype Vaccine with IL-2 for Advanced Melanoma, Kenneth A. Foon, M.D., Principal Investigator, 11/1/98 - 10/30/00, \$145,646 (total direct and indirect cost).

Amgen, High Grade Lymphoma, Kenneth A. Foon, M.D., Principal Investigator, 2/1/95 - 2/1/99, \$15,000 (\$11,910 direct costs, \$3,090 indirect cost).

NIH R01 CA72018-01, Ganglioside GD2 as Target for Immunotherapy in Melanoma, Kenneth A. Foon, M.D., Co-Investigator, 8/1/96 - 6/30/01, \$1,142.854 (direct cost), \$1,679,995 (total cost).

Titan Pharmaceutical, Inc., Anti-Idiotype Antibody Vaccines, Kenneth A. Foon, M.D., Co-Principal Investigator, 7/1/96 - 6/30/01, \$1,750,000 (total direct cost).

NCI R03 CA72468-01, Comparison of Alum and QS-21 Based Anti-Idiotype Vaccines, Kenneth A. Foon, M.D., Principal Investigator, 12/1/96 - 11/30/98, \$147,000 (direct and indirect cost).

NCI U01 CA65748-01, New Therapeutic Approaches to Breast Cancer, Kenneth A. Foon, M.D., Principal Investigator, 12/1/94 - 11/30/98, \$842,019 (direct cost), \$412,589 (indirect cost).

NIH NCI U01CA65748, "New Therapeutic Approaches to Breast Cancer", Principal Investigator, Kenneth A. Foon, M.D., 1/1/95 – 12/31/99.

NIH NCI R03 CA68629, "Comparison of Alum and QS-21 Based Anti-Id Vaccione", Principal Investigator Kenneth A. Foon, M.D., 11/01/96 – 10/31/99

NIH RO1 CA80968-01, "Anti-Idiotype Antibody Vaccine Therapy of Human Colorectal Cancer," Consultant, Kenneth A. Foon, MD, 9/1/99 - 7/31/03.

2. Seminars and invited lectureships related to your research. (Five years)

Anti-Idiotype Cancer Vaccines, The Children's Hospital Research Foundation Immunotherapy Conference, Cincinnati, OH, January 31, 2000.

Anti-Idiotype Antibodies Directed Against Gangliosides. Melanoma at the Millennium Conference, Phoenix, AZ, February 17, 2000

Anti-idiotype Vaccine that Mimics CEA: Novel therapeutic approach to colon cancer treatment. Case Western University, Ireland Cancer Center, Blood Club Seminar, Cleveland, OH, February 25, 2000.

Clinical and Immune Responses in Resected Colon Cancer patients Treated with Anti-Idiotype Monoclonal Antibody Vaccine that mimics the CarcinoembryonicAntigen. International Conference on Advances in Cancer Immunotherapy, Princeton, NJ, March 2 - 4, 2000.

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. 2nd Annual Walker's Cay Colloquium, Albert B. Sabin Vaccine Institute, Abaco, Bahamas, March 8 – 12, 2000.

The Barrett Cancer Center in the New Millennium. UC Board of Trustees, University of Cincinnati, Cincinnati, OH March 29, 2000.

Clinical Trials of Immunotherapeutics and Immunologic Monitoring. American Association for Cancer Research, April 3 – 4, 2000.

Targeted Therapies in the Treatment of Lymphoma, University of Louisville, Louisville, KY, Anti-idiotype Vaccine that Mimics the Carcinoembryonic Antigen. Dept. of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH April 20, 2000.

Cancer Vaccines. Sabin 40th Annual Anniversary Celebration, University of Cincinnati, Cincinnati, OH April 28, 2000.

The Barrett Cancer Center and the New Millennium. UC Medical Center Orientation, Cincinnati, OH May 4, 2000.

Non-Hodgkin's Lymphoma. Miami Valley Hospital Tumor Board, Dayton, OH May 5, 2000.

Colorectal Cancer: Molecular Genetics and Therapeutic Advances. University-Wide Clinical Pathology Conference, Cincinnati, OH May 10, 2000.

Cancer Vaccines. 2000 American Society of Clinical Oncology, New Orleans, LA. May 19 – 22, 2000

Vaccine Therapies of Malignant Melanoma. Hematology-Oncology Grand Rounds, University of Cincinnati, Cincinnati, OH. May 26, 2000.

Welcome and Introduction, Cancer Survivor's Day, University of Cincinnati, Cincinnati, OH, June 4, 2000.

Vaccine Approaches to the Adjuvant Treatment of Colorectal Cancer. The Barrett Cancer Center and University of Cincinnati Annual Cancer Conference. Cincinnati, OH June 17, 2000.

Chronic Lymphoid Leukemias. Hematology-Oncology Grand Rounds Conference, University of Cincinnati, Cincinnati, OH. September 29, 2000.

Overview of Immune Flow Cytometry of Leukemias and Lymphomas. The Barrett Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH. October 7, 2000.

An Update on Cancer Vaccines. 12th Annual Western North Carolina Cancer Conference, Asheville, North Carolina, October 27, 2000.

Rubitecan: An Effective New Therapy in Pancreatic Cancer. Chemotherapy Foundation Symposium XVIII, New York City, New York, November 8, 2000.

Vaccine in the Treatment of GI Malignancies. Gastrointestinal Cancer Research Conference 2000, Orlando, Florida, November 16 – 18, 2000.

Anti-Idiotype Antibody that Mimics Carcinoembryonic Antigen: Novel new Approach to Colon Cancer Immunotherapy. The Molecular Medicine of Colorectal Cancer, Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico, February 1 – 2, 2001.

Expanding Options in the Treatment of Non-Hodgkin's Lymphoma". Medical City Tumor Conference, Medical City Dallas Hospital, Dallas, TX. March 21, 2001.

Monoclonal Antibodies in Combination with Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma. IDEC Pharmaceuticals Corporation, Dallas, TX. March 21, 2001.

Clinical Results: A Fully Human Anti-EGFr Antibody In Patients With Advanced Cancer: Molecular Targets and Cancer Therapeutics, AACR-NCI-EORTC International Conference. October 29 – November 2, 2001

Effects of ABX-EGF, A Fully Human Anti-EGFr Antibody, in Patients with Advanced Cancer. Cancer Research Institute Antibodies 2002 Symposium: New York, NY, March 19 – 20, 2002

Current Status of Vaccine Therapy in Malignancies. Moving Beyond The Ordinary; Fourth Annual Palm Beach Cancer Symposium, Delray Beach, FL., March 22-23, 2002.

ABX-EGF, A Fully Human Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (MAb) In Patients With Advanced Cancer. Phase 1 Clinical Trials: American Society of Clinical Oncology: Gaylord Palms Resort and Convention Center, Kissimmee, FL. May 19 – 21, 2002.

ABX-EGF, A Fully Human Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (MAb) for the Treatment of Patients with a Variety of EGFr Positive Malignancies. Anti-Cancer Drug Discovery & Development Summit 2002: Princeton, NJ, June 17 – 19, 2002.

ABX-EGF, A Fully Human Anti-EGFR Monoclonal Antibody For The Treatment Of Advanced Caner. First International Congress on Targeted Therapies: Washington, DC, August 16-18, 2002.

Monoclonal Antibodies/Other Immune Directed Strategies In Cancer Management. Emerging Therapeutics in Cancer: Update on Prostate Cancer, 7th Annual National VA Oncology Symposium, Alexandria, VA, October 2 – 4, 2002.

Nipent® (pentostatin) Experience in the Treatment of CLL. 2005 ASCO Annual Meeting, May 13-17, 2005.

International Vaccine Conference Anti-Idiotype Vaccines Mimicking the CEA and GD-2 Gangliosides, Italy, 2004.

Grand Rounds, University of Pittsburgh School of Pharmacy, Anti-Idiotype Vaccines Mimicking the CEA and GD-2 Gangliosides, Italy, 2004.

ECOG 2005 Fall Meeting, Anti-Idiotypic Antibody That Mimics the GD2 Ganglioside, Tampa, FL, Nov. 20, 2005.

Reason for Hope – Advances in the Treatment of CLL – “Reason to Hope” Series. UPMC St. Cancer Center – St. Clair, Upper St. Clair, PA, Nov. 30, 2005

3. Other Research Related Activities

Patents

Tri-Gem (1A7)

Patent Number: 5,612,030
Date of Patent: 3/18/97

“Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma”

TriAb (11D10)

Pending Serial Number: 08/766,350
Date Filed: 12/13/96
“Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof”

CeaVac (3H1)

Pending Serial Number: 08/579940
Date Filed: 12/28/95 (whole antibody)
“Murine monoclonal anti-idiotypic antibody 3H1”

Pending Serial Number: 08/579916
Date Filed: 12/28/95

Member, TVC Advisory Board 2006-present

Member, Spectrum Advisory Board 2006-present

Faculty, Berlex Speakers Bureau 2006-present

Faculty, Genentech Speakers Bureau 2006-present

Faculty, CBCE Speakers Bureau 2003-present

| | |
|--|--------------|
| Esai Pharmaceutical Advisory Board | 2003-present |
| Scientific Advisor, Automated Cell | 2003-present |
| Supergen Scientific Advisory Board | 2003-present |
| Editorial Board, Journal of Clinical Immunology | 1993-present |
| Member, Scientific Advisory Board, National Surgical Adjuvant Breast and Bowel Project | 1996-present |
| Editorial Board, Cancer Biotherapy & Radiopharmaceuticals | 2005-present |
| Editor, Journal of Experimental Biology and Medicine, Translational Research Section | 2005-present |
| Co-Editor, Expert Opinion on Biological Therapy, Future Perspectives Section | 2006-present |
| Associate Editor, Clinical Cancer Research | 1998-present |
| Editorial Board, Journal of Immunotherapy | 1982-1996 |
| Clinical Sciences Study Section (Subcommittee 4) Division of Research Grants | 1986-1990 |
| Associate Editor, Cancer Research | 1987-2003 |
| Associate Editor, Antibodies, Immunoconjugates and Radiopharmaceuticals | 1987-1990 |
| Editorial Board, Contemporary Oncology | 1990-1994 |
| Grants Review Committee for the American Cancer Society | 1993-1996 |
| Board of Directors, The Society for Biological Therapy | 1995-1997 |
| Editorial Board, Journal of Biotherapy | 1995-2000 |
| Board of Advisors, NeoRx Corporation, | 1985-1988 |

Seattle, WA

| | |
|--|-------------------|
| P01, Member, Memorial Sloan Kettering Cancer Center, NCI Site Visit committee, New York, NY | May 1, 1985 |
| P01, Member, NCI Special Review Committee | October 1, 1985 |
| P01, Member, Stanford Medical Center, NCI Site Visit Committee, Stanford, CA | October 1, 1985 |
| National Research Service Award Advisory Committee, National Institute of Health | 1985-1989 |
| | |
| P01, University of California at Davis, Sacramento, CA, Member, NCI Site Visit Committee | March 1, 1988 |
| P01, Member, Immunomedics, Site Visit Committee, Morris Plains, NJ | December 5, 1990 |
| P01, Stanford Medical Center, Member, NCI Site Visit Committee, Stanford, CA | November 11, 1991 |
| P30, Member, University of Nebraska Cancer Center, NCI Site Visit Committee, Omaha, NE | February 10, 1992 |
| P50, Member, NCI Special Study Section for AIDS Center Grants | July 13, 1993 |
| Board of Advisors, Inex Pharmaceuticals Corp. Vancouver, B.C. | 1994-1995 |
| Health & Environment Laboratories, Eastman Kodak Company, Rochester, NY | 1994-1996 |
| PO1, University of California at Davis, Sacramento, CA, NCI Site Visit Committee Chairman | April 13, 1994 |
| 2P01CA59326-03, Gene Therapy for Cancer, University of California at Los Angeles, Member, NCI Site Visit Committee | June 19, 1994 |
| Scientific Review Panel, Israel Cancer Research | 1995-2001 |

Fund, New York, NY

2P01CA4499108, Theray of Lymphoma/Leukemia February 14, 1995
with Monoclonal Antibodies, Fred Hutchinson
Cancer Research Center, Member, NCI Site Visit
Committee

1P30CA6953301, Oregon Cancer Center, June 12, 1995
Member, NCI Site Visit Committee

1P30CA6953301, Oregon Cancer Center, Member August 3, 1995
NCI Site Visit Committee

NSABP Scientific Advisory Board, Operations February 6, 1996
Center Site Visit, Pittsburgh, PA

2P01CA5935005, Memorial-Sloan Kettering July 7, 1996
Cancer Center, Gene Therapy Program, NCI
Site Visit Committee Chairman

1P30CA6953301A1 Oregon Cancer Center, October 7, 1996
Member, NCI Site Visit Committee

Director, Scientific Advisory Board, Titan 1996-2001
Pharmaceuticals, Inc., South San Francisco, CA

NCI Scientific Review Group-Subcommittee H 1997-2001

NCI Clinical Oncology Study Section 1999-2001

ACOSOG Site Visit, Chicago, IL Sept. 21, 1999

SuperGen Advisory Board Meeting, Phoenix, AZ January 15, 2000

SuperGen Advisory Board Meeting, Phoenix, AZ January 13-16, 2000

NCI GI Intergroup State-of-Science Symposium February 15, 2000

NCI Clinical Oncology Study Section, March 20, 2000
Bethesda, MD

IDE Pharmaceuticals Meeting, San Diego May 7-8, 2000
CA

American College of Surgeons/Titan May 16, 2000
Pharmaceutical Meeting, Chicago, IL

NCI NIH Scientific Review Group-Subcommittee H Site Review, Rochester, MN June 7-9, 2000

SuperGen, Rubitecan Advisory Board Meeting Maui, HI June 13-17, 2000

American College of Surgeons Semianual Meeting, Chicago, IL June 24, 2000

NCI Clinical Oncology Study Section, Bethesda, MD July 7-14, 2000

Abbott Pharmaceutical Advisory Panel, Chicago, IL Dec. 8-9-, 2000

Fulcrum Renal Cell Advisory Board Mtg. New York Jan. 14-15, 2001

NCI Breast Intergroup Retreat, Washington, DC Jan. 18-19, 2001

NCI Scientific Review Group-Subcommittee H Teleconference March 15, 2001

PO1, Member, NCI Scientific Review Group November 2005

ICRF Scientific Review Group March 2006

LIST OF CURRENT RESEARCH INTERESTS:

Current grant funded research is a phase III clinical trial using the TriGem anti-idiotype vaccine for melanoma developed in our laboratories. At the UPCI, I am developing new protocols for a variety of hematologic malignancies including Hodgkin's disease, lymphomas, chronic lymphocytic leukemia, multiple myeloma, chronic myelogenous leukemia, acute myelogenous leukemia, and myelodysplastic syndromes. A collaboration with the NCI and Therion Biopharm for a vaccine therapy of CLL has been established. New collaborations with UPCI investigators are ongoing to generate dendritic cell vaccines for B-cell lymphoma and multiple myeloma. We have established a chronic lymphoid malignancies/multiple myeloma clinical center that will allow us to expand these translational research programs. In the area of solid tumors, we are establishing new areas of translational research with UPCI investigators generating a variety of dendritic cell vaccine approaches, and with investigators at the National Cancer Institute and Biotechnology companies using viral vectors for gene therapy.

SERVICE:**1. University and Medical School**

| | |
|--------------|---|
| 1989 - 1990 | Search Committee for Chairman, Department of Radiation Oncology, Roswell Park Cancer Institute |
| 1989 - 1990 | Search Committee for Chairman, Department of Cytogenetics, Roswell Park Cancer Institute |
| 1999 -2001 | Oncology-Hematology Care Executive Committee, University of Cincinnati |
| 1999 -2001 | Ohio Cancer Incidence Surveillance System Advisory Board |
| | Ohio Department of Health |
| 1999 -2001 | Hematology-Oncology Fellow Evaluation Committee, University of Cincinnati |
| 1989 - 1990 | Search Committee for Chairman, Department of Pediatrics, Roswell |
| 1990 | Head, Search Committee for Infectious Disease Specialist, Roswell Park Cancer Institute |
| 1990 - 1991 | Search Committee for Chairman, Department of Microbiology, SUNY |
| 1989 - 1990 | Radiation Safety Committee, Roswell Park Cancer Institute |
| 1989 - 1990 | Quality Assurance Committee, Roswell Park Cancer Institute |
| 1989 - 1991 | American Society of Hematology, Neoplastic Committee |
| 1990 | Head, Search Committee for Pulmonologist/Intensivist, Roswell Park |
| 1991 | Head, Search Committee for Cardiologist, Roswell Park Cancer Institute Cancer Institute |
| 1990 - 1991 | Vice President, Medical Staff, Roswell Park Cancer Institute |
| 1993 | Head, Search Committee for Chairman of Radiation Medicine, |
| 1989 - 1991 | American Society of Clinical Oncology, Program Committee |
| 1991 - 1992 | American Association for Cancer Research, Program Committee |
| 1992 - 1994 | Clinical Immunology Society, Program Committee |
| 1992 -1989 | Internal Medicine Chairman's Advisory Committee |
| 1994 -1999 | Liaison Committee on Medical Education, University of Kentucky |
| 1994 - 1996 | Medical Center Clinical Sciences Area Advisory Committee, University of Kentucky |
| 1996 - 1999 | General Clinical Research Center Advisory Committee, University of Kentucky |
| 1999 -2001 | Chair, Cancer Steering Committee, University Hospital, University of Cincinnati |
| 1999 -2001 | Vontz Steering Committee, University of Cincinnati |
| 1999 -2001 | Chair, Internal Advisory Committee, Barrett Cancer Center, University of Cincinnati |
| 1999 -2001 | Chair, Scientific Review Committee, Barrett Cancer Center, University of Cincinnati |
| 2003-Present | Director of the University of Pittsburgh Cancer Institute, GCRC |

2003-Present Member of the University of Pittsburgh Medical Center GCRC Advisory Board
2005-Present Co-Chair, PAC3, Pennsylvania Cancer Control Consortium
2003-Present Co-Leader, Biologic Therapeutics Program, University of Pittsburgh
2003-Present Co-Leader, Hematologic Malignancy Program, University of Pittsburgh
2003-Present Director of Clinical Investigations, University of Pittsburgh Cancer Institute

2. Community Activities

1985-1987 Board of Trustees, Michigan Chapter, Leukemia Society of America
1994-1995 American Cancer Society, Board of Directors, Fayette County Unit
1994 - 1996 Health and Environment Laboratories, Eastman Kodak Company,
 Rochester, NY
1998 Department of Insurance, Commonwealth of Kentucky